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A B S T R A C T
Background
Preterm infants are at risk of exhausting their body iron stores much earlier than healthy term newborns. It is widespread practice to give
enteral iron supplementation to preterm and low birth weight infants to prevent iron deficiency anaemia. However, it is unclear whether
supplementing preterm and low birth weight infants with iron improves growth and neurodevelopment. It is suspected that excess
exogenous iron can contribute to oxidative injury in preterm babies, causing or exacerbating conditions such as necrotising enterocolitis
and retinopathy of prematurity. Additionally, the optimal dose and timing of commencement and cessation of iron supplementation
are uncertain.
Objectives
To evaluate the effect of prophylactic enteral iron supplementation on growth and neurodevelopmental outcomes in preterm and low
birth weight infants. The secondary objectives were to determine whether iron supplementation results in improved haematological
parameters and prevents other causes of morbidity and mortality.
Search methods
We used the standard search strategy of the Cochrane Neonatal Review Group. We searched Cochrane Central Register of Controlled
Trials (CENTRAL) (The Cochrane Library 2011, Issue 8), MEDLINE (1951 to August 2011), CINAHL (1982 to August 2011) and
conference proceedings and previous reviews.
Selection criteria
Randomised controlled trials (RCTs) and quasi-randomised trials that compared enteral iron supplementation with no iron supple-
mentation, or different regimens of enteral iron supplementation in preterm or low birth weight infants or both.
Data collection and analysis
We extracted data using the standard methods of the Cochrane Neonatal Review Group. Both review authors separately evaluated
trial quality and data extraction. We synthesised data using risk ratios (RRs), risk differences (RDs) and weighted mean differences
(WMDs). Where data about the methodology and results or both were lacking, we made an attempt to contact the study authors for
further information.
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Main results
We included twenty-six studies (2726 infants) in the analysis. The heterogeneity of participants, methods and results precluded an
extensive quantitative synthesis. Of the 21 studies comparing iron supplementation with controls, none evaluated neurodevelopmental
status as an outcome. Of thirteen studies reporting at least one growth parameter as an outcome, only one study of poor quality
found a significant benefit of iron supplementation. Regarding haematological outcomes, no benefit for iron supplementation was
demonstrated within the first 8.5 weeks of postnatal life (16 trials), except by two poor quality studies. After this age, most studies
reported a higher mean haemoglobin in iron-supplemented infants. We were only able to include a limited number of studies in a
quantitative meta-analysis, which suggested the haemoglobin concentration in iron-supplemented infants was higher by about 6 g/L
at six to nine months. One study comparing high dose and low dose iron supplementation monitored neurodevelopmental outcome
for one year, without finding any significant difference between the groups. One study comparing early versus late commencement of
iron supplementation found no difference in cognitive outcome, but an increased rate of abnormal neurological examination in the late
iron group at five years of age. The studies comparing high and low doses of iron indicated that there was no discernible haematological
benefit in exceeding ’standard’ doses of iron (i.e. 2 mg/kg/day to 3 mg/kg/day).
Authors’ conclusions
The available data suggest that infants who receive iron supplementation have a slightly higher haemoglobin level, improved iron stores
and a lower risk of developing iron deficiency anaemia when compared with those who are unsupplemented. However, it is unclear
whether iron supplementation in preterm and low birth weight infants has long term benefits in terms of neurodevelopmental outcome
and growth. The optimum timing and duration of iron supplementation remains unclear.
P L A I N L A N G U A G E S U M M A R Y
Enteral iron supplementation in preterm and low birth weight infants
This review examined whether providing iron supplementation is beneficial for preterm and low birth weight infants. The potential
benefits included improvements in the level of red blood cells and stored iron in their blood. In the longer term, it was thought that
iron supplementation might improve the babies’ growth and development.We identified 25 randomised controlled trials (RCTs) which
were relevant to this topic. We concluded that the long term benefits of iron supplementation for preterm and low birth weight babies
remain uncertain. Regarding red blood cell and iron levels, it was found that in the first year of life, after two months of age, iron
supplementation may result in slightly higher iron stores and red blood cell levels, and lower rates of iron deficiency anaemia. However,
there was a lot of variability between different studies. More RCTs are needed, using well defined patient groups.
B A C K G R O U N D
Description of the condition
Most of the healthy termnewborn’s iron stores have been laid down
during the third trimester. Therefore, this important acquisition
of iron stores is reduced in preterm infants. The preterm infant has
a higher requirement for iron due to proportionally more rapid
postnatal growth than that of the term infant. This exacerbates
the total body iron deficit of the preterm infant, as iron stores
decrease over the first three months of postnatal life. While non-
iron supplemented term infants have not been shown to develop
biochemical or haematological iron deficiency before six months
of age, there is a high rate of iron deficiency anaemia before this
age in preterm infants fed only breast milk (Doyle 1992).
Humanmilk contains about 0.5mg/Lof elemental iron,while iron
fortified formulas contain at least ten times that amount of iron.
Despite their limited erythropoiesis, breast fed preterm infants are
in negative iron balance for at least the first 30 days after birth,
due to obligatory intestinal and insensible skin loss of iron (Shaw
1982).
For these reasons, the American Academy of Pediatrics (AAP) rec-
ommends supplementation of preterm neonates with 2 mg/kg/
day of enteral iron, either as an iron mixture, or in the form of
iron-fortified formula. It is recommended that this supplementa-
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tion commence within two months of birth, and be continued
until 12 months of age (Baker 2010).
Description of the intervention
Several studies have demonstrated higher haemoglobin or ferritin
levels in low or very low birth weight infants who were supple-
mented with enteral iron compared with breast milk or unfortified
cow milk formula (Hall 1993; Lundstrom 1977). However, the
evidence is unclear as to whether this improvement in biochemical
and haematological parameters is associated with a difference in
neurodevelopmental outcomes or growth parameters in preterm
and low birth weight infants.
How the intervention might work
Studies in term infants have demonstrated a correlation between
iron deficiency anaemia and reduced performance in developmen-
tal testing (Lozoff 1987; Walter 1989). It is hypothesised that the
provision of enteral iron supplementation to preterm and lowbirth
weight infants, who are at particular risk of iron deficiency, will re-
sult in improved neurodevelopmental outcomes by avoiding iron
deficiency.
Why it is important to do this review
The potential risks of iron supplementation need to be considered.
Iron overload can occur in the setting of multiple blood transfu-
sions (Ng 2001). High transfusion requirements early in life have
been shown to be associated with a greater risk of retinopathy
of prematurity (Dani 2001; Hesse 1997; Inder 1997). Increased
body iron load has also been hypothesised to increase the risk of
chronic lung disease (Cooke 1997). Putative risks have been sug-
gested related to iron’s ability to cause oxidative injury. In addition
to the direct oxidative property of iron, large iron doses decrease
the absorption of the anti-oxidant vitamin E, thus exacerbating
anaemia in vitamin E deficient neonates (Doyle 1992).
Iron fortification of formulas has been suspected, but not proven,
to cause a range of gastrointestinal symptoms in infants (Hyams
1995).While necrotising enterocolitis (NEC) has not been explic-
itly linked to enteral iron supplementation, it is recognised that
human milk is protective against NEC (McGuire 2003).
If enteral iron supplementation is accepted as being a beneficial
intervention, the optimum dose, time of initiation and duration
of treatment need to be defined.
O B J E C T I V E S
The primary objective of this systematic review was to evaluate the
effect of prophylactic enteral iron supplementation on growth and
neurodevelopmental outcomes of preterm and low birth weight
infants. The secondary objectives were to determine whether iron
supplementation results in improved haematological parameters
and prevents other causes of morbidity and mortality.
We planned separate comparisons of:
1. trials that compared enteral iron supplementation versus no
supplementation; and
2. trials that compared different regimens of enteral iron
supplementation (dose, duration and timing of initiation).
Data permitting, the following subgroup analyses were planned.
1. Type of milk feeding: trials involving exclusively formula-
fed infants and those involving exclusively or partially breast fed
infants.
2. Postnatal age of commencement of iron supplementation:
’early commencement’ (less than 28 days postnatal) and ’late
commencement’ (28 days or more postnatal).
3. Daily dose of supplemental iron administered: ’low dose’ (2
mg/kg/day or less) and ’high dose’ (more than 2 mg/kg/day).
4. Duration of iron supplementation: ’short duration’ (six
months or less) and ’long duration’ (more than six months).
5. Gestational age and birth weight of participants, or both:
less than or equal to 33 completed weeks’ or less than 1500 g and
more than 33 completed weeks’ or 1500 g or more.
M E T H O D S
Criteria for considering studies for this review
Types of studies
RCTs and some non-RCTs (quasi-randomised) in which individ-
ual infants were either:
1. allocated to receive enteral iron supplementation (of at least
1 mg/kg/day), and compared with a control group (placebo or
no drug or < 1 mg/kg/day of iron); or
2. allocated to different regimens of enteral iron
supplementation (in regard to dosage, duration and timing of
initiation).
We excluded cross-over studies.
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Types of participants
Infants born preterm (before 37 weeks’ completed gestation), or
of low birth weight (< 2500 g).
Types of interventions
1. Enteral iron supplement of at least 1 mg/kg/day versus no
supplementation (i.e. < 1 mg/kg/day).
2. Comparison of different regimens of enteral iron
supplementation, in regard to the dose, duration, and timing of
initiation of iron supplementation.
We specifically excluded studies in which the subject infants were
receiving concurrent treatment with erythropoietin.
Types of outcome measures
Primary outcomes
1. Standardised measures of neurodevelopmental outcome
(e.g. Bayley MDI and PDI), at 12 months or less, two years or
less and five years or less.
2. Length, weight and head circumference at 12 months or
less, two years or less and five years or less.
Secondary outcomes
1. Blood haemoglobin concentration and mean corpuscular
volume (MCV), at six to eight weeks, three to four months, six
to nine months and 12 months.
2. Serum ferritin concentration, transferrin saturation and
total iron binding capacity (TIBC), at six to eight weeks, three to
four months, six to nine months and 12 months.
3. Severe anaemia (haemoglobin level < 8 g/dL or hematocrit
< 0.25).
4. Mortality (during primary hospitalisation and before two
years of life).
5. Chronic lung disease (persisting oxygen requirement at 36
weeks postmenstrual age).
6. Retinopathy of prematurity (Stage 3 and above, and all
stages).
7. NEC (Bell’s stage 2 or above).
8. Incidence of invasive infection as determined by culture of
bacteria or fungus from blood, cerebrospinal fluid, urine or from
a normally sterile body space.
9. Feed intolerance defined as a requirement to cease enteral
feeds and commence parenteral nutrition.
10. Total duration of primary hospitalisation.
11. Requirement for readmission to hospital in the first year of
life.
Search methods for identification of studies
Electronic searches
We used the standard search method of the Cochrane Neonatal
Review Group.
We searched the Cochrane Central Register of Controlled Trials
(CENTRAL) (The Cochrane Library 2011, Issue 8), ’OldMedline’
(1951 to 1965), MEDLINE (1966 to August 2011), CINAHL
(1982 to August 2011) and the Oxford Database of Perinatal Tri-
als. We used the following search strategy.
MeSH search terms ’Iron/tu [Therapeutic use]’, ’Iron/ad [Ad-
ministration and dosage]’, ’Iron, Dietary’, ’Ferrous compounds/
tu [Therapeutic use]’, or text words ’ferrous sulphate’, ’ferrous sul-
fate’, ’ferrous gluconate’
AND
MeSH search term ’infant’, or text words ’preterm’, ’premature’,
’low birth weight’
We also searched clinical trials registries for ongoing or re-
cently completed trials (clinicaltrials.gov; controlled-trials.com;
and who.int/ictrp).
Searching other resources
In addition, we included previous reviews (including cross refer-
ences), abstracts, conference and symposia proceedings published
in Pediatric research. We did not restrict searches by language of
publication. We contacted lead investigators of included studies,
where possible, to clarify methods and results and identify other
published or unpublished studies which fulfil the inclusion crite-
ria.
Data collection and analysis
We used the standard methods of the Cochrane Neonatal Review
Group.
Selection of studies
We screened the title and abstract of all studies identified by the
above search strategy. We obtained the full articles for all poten-
tially relevant trials. We re-assessed the full text of any potentially
eligible reports and excluded those studies that did not meet all of
the inclusion criteria. We resolved any disagreements by consen-
sus.
Data extraction and management
We used a data collection form to aid extraction of relevant infor-
mation from each included study. Both review authors extracted
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the data separately. We discussed any disagreements until consen-
sus was achieved. We contacted the trialists for further informa-
tion if data from the trial reports were insufficient.
Assessment of risk of bias in included studies
We used the criteria and standard methods of the Cochrane
Neonatal Review Group to independently assess the methodolog-
ical quality of any included trials in terms of allocation conceal-
ment, blinding of parents or caregivers and assessors to interven-
tion, and completeness of assessment in all randomised individu-
als. We requested additional information from the trial authors to
clarify methodology and results as necessary.
We included this information in the Characteristics of included
studies and Risk of Bias tables. We used the following criteria to
complete the Risk of Bias table:
1. Random sequence generation (checking for possible
selection bias). For each included study, we categorised the
method used to generate the allocation sequence as:
i) low risk (any truly random process e.g. random
number table; computer random number generator);
ii) high risk (any non-random process e.g. odd or even
date of birth; hospital or clinic record number); or
iii) unclear risk of bias.
2. Allocation concealment (checking for possible selection
bias). For each included study, we categorised the method used
to conceal the allocation sequence as:
i) low risk (e.g. telephone or central randomisation;
consecutively numbered sealed opaque envelopes);
ii) high risk (open random allocation; unsealed or non-
opaque envelopes, alternation; date of birth); or
iii) unclear risk of bias.
3. Blinding (checking for possible performance bias). For each
included study, we categorised the methods used to blind study
participants and personnel from knowledge of which
intervention a participant received. We assessed blinding
separately for different outcomes or classes of outcomes. We
categorised the methods as:
i) low risk, high risk or unclear risk for participants;
ii) low risk, high risk or unclear risk for personnel; and
iii) low risk, high risk or unclear risk for outcome
assessors.
4. Incomplete outcome data (checking for possible attrition
bias through withdrawals, dropouts or protocol deviations). For
each included study and for each outcome, we described the
completeness of data including attrition and exclusions from the
analysis. We noted whether attrition and exclusions were
reported, the numbers included in the analysis at each stage
(compared with the total randomised participants), reasons for
attrition or exclusion where reported, and whether missing data
were balanced across groups or were related to outcomes. Where
sufficient information was reported or supplied by the trial
authors, we re-included missing data in the analyses. We
categorised the methods as:
i) low risk (< 20% missing data);
ii) high risk (≥ 20% missing data); or
iii) unclear risk of bias.
5. Selective reporting bias. For each included study, we
described how we investigated the possibility of selective outcome
reporting bias and what we found. We assessed the methods as:
i) low risk (where it is clear that all of the study’s pre-
specified outcomes and all expected outcomes of interest to the
review have been reported);
ii) high risk (where not all the study’s pre-specified
outcomes have been reported; one or more reported primary
outcome(s) were not pre-specified; outcomes of interest are
reported incompletely and so cannot be used; and the study fails
to include results of a key outcome that would have been
expected to have been reported); or
iii) unclear risk of bias.
6. Other sources of bias. For each included study, we
described any important concerns we had about other possible
sources of bias (for example, whether there was a potential source
of bias related to the specific study design or whether the trial
was stopped early due to some data-dependent process). We
assessed whether each study was free of other problems that
could put it at a:
i) low risk;
ii) high risk; or
iii) unclear risk of bias.
If needed, we planned to explore the impact of the level of bias
through undertaking sensitivity analyses.
Measures of treatment effect
We used the standard methods of the Cochrane Neonatal Re-
view Group.We performed statistical analyses using ReviewMan-
ager software (RevMan 2011). We analysed continuous data us-
ing weighted mean difference (WMD). Where appropriate data
were available, we analysed categorical data using risk ratio (RR),
risk difference (RD) and the number needed to benefit or harm
(NNTB/NNTH).We reported the 95%Confidence interval (CI)
on all estimates.
Unit of analysis issues
Where studies presented data in non-SI units, we performed con-
version to SI units (International System of Units) when extract-
ing the data. Overall, difference in units of analysis was not a sig-
nificant obstacle in this review.
Dealing with missing data
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Where studies published data with insufficient detail to permit
their inclusion in quantitative meta-analysis, we contacted the au-
thors to provide additional detail. If no further detail was received,
the studies remained eligible for inclusion in the review, but were
not included in the pooled quantitative analysis.
Assessment of heterogeneity
If meta-analysis was possible, we examined the treatment effects
of individual trials and heterogeneity between trial results by in-
specting the forest plots. We assessed the impact of heterogeneity
in themeta-analysis using a measure of the degree of inconsistency
in the studies’ results (I2 statistic). If we found statistical hetero-
geneity, we explored the possible causes (for example, differences
in study quality, participants, intervention regimens or outcome
assessments) using post hoc subgroup analyses. We used a fixed-
effect model for meta-analyses.
Assessment of reporting biases
Where possible, we asked the authors of the included studies to
notify us of relevant unpublished data. This would permit an as-
sessment of the likelihood of reporting biases.
Data synthesis
The meta-analysis was performed using Review Manager software
(RevMan 2011), supplied by the Cochrane Collaboration. For
estimates of typical RR and RD, we used the Mantel-Haenszel
method. For measured quantities, we used the inverse variance
method. We used the fixed-effect model for all meta-analyses.
Subgroup analysis and investigation of heterogeneity
We planned separate comparisons of:
1. trials that compared iron supplementation versus no
supplementation; and
2. trials that compared different regimens of iron
supplementation (dose, duration and timing of initiation).
Data permitting, we had planned to conduct the following sub-
group analyses.
1. Type of milk feeding: trials involving exclusively formula-
fed infants and those involving exclusively or partially breast-fed
infants.
2. Postnatal age of commencement of iron supplementation:
’early commencement’ (less than 28 days postnatal) and ’late
commencement’ (28 days or more postnatal).
3. Daily dose of supplemental iron administered: ’low dose’ (2
mg/kg/day or less) and ’high dose’ (more than 2 mg/kg/day).
4. Duration of iron supplementation: ’short duration’ (six
months or less) and ’long duration’ (more than six months).
5. Gestational age and birth weight of participants, or both:
less than or equal to 33 completed weeks’ or less than 1500 g and
more than 33 completed weeks’ or 1500 g or more.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of studies awaiting classification.
Results of the search
We identified 64 studies for detailed assessment.
Included studies
We included twenty-six trials (see table Characteristics of included
studies). Twenty-one trials compared enteral iron supplementa-
tion with no supplement or minimal supplementation (less than
1 mg/kg/day). Four trials specifically compared early versus late
commencement of iron supplementation (Arnon 2009; Halliday
1983; Jansson 1979; Steinmacher 2007); Arnon 2009 also tested
iron versus no or minimal iron. Three studies compared high dose
iron supplementation with “standard” dose iron supplementation
(Barclay 1991, which also tested iron versus no or minimal iron;
Friel 2001; Groh-Wargo 1990). In addition to comparing with
placebo, Berglund 2010 compared a low dose (2 mg/kg/day) with
a very low dose (1 mg/kg/day). None of the trials compared the
effect of longer duration iron supplementation with shorter dura-
tion.
Twelve of the trials were conducted in North America (Berseth
2004; Diamond 1958; Friel 2001; Gorten 1964; Groh-Wargo
1990; Gross 1985; Hall 1993; Melhorn 1971; Melnick 1988;
Quilligan 1954; Reedy 1952; Rudolph 1981) and the remainder
in a variety of countries including the United Kingdom (Barclay
1991; Coles 1954; Griffin 1999; Halliday 1983), Germany (Franz
2000; Steinmacher 2007), India (Aggarwal 2005; Sankar 2009),
Finland (Hanninen 1961; Lundstrom 1977), Sweden (Berglund
2010; Jansson 1979), Brazil (Ferlin 1998) and Israel (Arnon 2009).
The span of publication dates was wide, from 1952 to 2010. The
spread of dates was very even, with four from the 1950s, two from
the 1960s, three from the 1970s, four from the 1980s, five from
the 1990s and eight from 2000 onwards.
Participants
A total of 2726 infants were enrolled in the 26 trials. Some 21 trials
involved only preterm infants (Arnon 2009; Berseth 2004; Coles
1954; Diamond 1958; Ferlin 1998; Franz 2000; Gorten 1964;
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Griffin 1999; Gross 1985; Halliday 1983; Hall 1993; Hanninen
1961; Jansson 1979; Lundstrom 1977; Melhorn 1971; Melnick
1988; Quilligan 1954; Reedy 1952; Rudolph 1981; Sankar 2009;
Steinmacher 2007). Another study (Groh-Wargo 1990) only spec-
ified a birth weight cut-off (< 1500 g), but most of the infants
included were likely to have been premature. Three other stud-
ies (Barclay 1991; Berglund 2010; Friel 2001) specifically studied
low birth weight (< 2500 g) infants of any gestation. A number
of the older trials simply recorded their subject infants as ’pre-
mature’ without specifying the gestation or birth weight cut-off
(Coles 1954; Diamond 1958; Quilligan 1954; Reedy 1952). One
trial exclusively enrolled term, low birth weight infants (Aggarwal
2005).
In five trials participating infants were exclusively formula fed
(Gorten 1964; Griffin 1999; Hall 1993; Melhorn 1971; Rudolph
1981). In four studies, the feeding method was not stated (
Diamond 1958;Hanninen 1961;Melnick 1988;Quilligan 1954).
In the remainder, the infants were either fully breast milk fed, or
given a combination of breast milk and formula.
Interventions
Most of the studies assessed the effect of iron supplementation
(generally between 2 mg/kg/day and 4 mg/kg/day of elemental
iron) versus placebo or no supplement. A number of the trials un-
dertaken before the mid-1960s prescribed much higher doses of
iron: Coles 1954, Diamond 1958, Hanninen 1961 and Quilligan
1954 all used more than 10 mg/kg/day, and in one trial up to
44 mg/kg/day (Coles 1954). Iron supplementation was usually
commenced between four and six weeks postnatally, although the
time of commencement was often defined by the establishment of
enteral feeding, such that the target or mean postnatal age of com-
mencement was not published. Four trials compared earlier (from
about two to three postnatal weeks) versus later (about eightweeks)
introduction of iron supplements (Arnon 2009; Halliday 1983;
Jansson 1979; Steinmacher 2007). Three trials compared “high”
doses versus “standard” doses of iron supplementation but there
was variation in the definition of dose. Specifically, Friel 2001 com-
pared 3.4 mg/kg/day versus 2.1 mg/kg/day; Groh-Wargo 1990
compared 4 mg/kg/day versus 2 mg/kg/day; and Barclay 1991
compared 7.1 mg/kg/day of iron versus 3.6 mg/kg/day. Berglund
2010 compared a low dose (2 mg/kg/day) with a very low dose (1
mg/kg/day).
For the purpose of comparison between trials, we converted all
doses of iron into a dose per kilogram body weight per day. The
body weight used for this calculation was the published mean
birth weight. If a mean birth weight was not provided, we made
an estimate based on the reported weights and gestational ages or
both, of the infants in the study. For studies of iron fortified infant
formulas, we often had to make an estimate of the daily intake
of formula; we applied the estimate of 160 ml/kg/day to all the
relevant studies.
Outcomes
Only two of the trials assessed neurodevelopmental outcomes (
Friel 2001; Steinmacher 2007). Eight reported anthropometric
data, usually weight gain, as an outcomemeasure (Aggarwal 2005;
Barclay 1991; Berglund 2010; Berseth 2004; Ferlin 1998; Hall
1993; Quilligan 1954; Reedy 1952). Most trials reported only
short term (up to four to six months corrected age) haematological
parameters as the primary outcomes. None of the trials reported
neonatal mortality, and quantitative measures of other neonatal
morbidities were not reported by most studies.
Excluded studies
We excluded thirty-six studies because they were not randomised
or quasi-randomised trials, or because the study population was
inappropriate (see table, Characteristics of excluded studies). Two
studies are awaiting foreign language translation (Hurgoiu 1986;
Neimann 1957).
Risk of bias in included studies
Overall, the methodological quality of the studies identified as
qualifying for inclusion was fair to poor (see table, Characteristics
of included studies). This is partly due to the age of many of the
studies. However, several more recent studies continued to use less
rigorous methodologies, such as quasi-randomisation.
Allocation
Of the 26 included studies, only eight are known to have an ade-
quate method of allocation concealment (Aggarwal 2005; Berseth
2004; Friel 2001; Gorten 1964; Griffin 1999; Halliday 1983;
Rudolph 1981; Sankar 2009), and in most of these studies we
only ascertained the adequacy of allocation concealment by di-
rect communication with the authors. Six of the studies were
quasi-randomised (Diamond 1958; Ferlin 1998; Hanninen 1961;
Lundstrom 1977; Quilligan 1954; Reedy 1952). In three cases,
the authors admitted to a lack of blinding of the allocation process
(Franz 2000;Melnick 1988; Steinmacher 2007). In the remaining
studies, a method of allocation concealment is not described.
Blinding
Most of the studies used placebo controls, or at least were com-
paring two formulas or preparations to which the participants and
study personnel were blind. Blinding of the outcome assessors is
vitally important for the primary outcomes of this review, namely
neurodevelopmental outcome and growth parameters. For the sec-
ondary outcomes such as haematological parameters, a natural
blinding is likely to have been inherent in the laboratory basis of
the tests, even in studies for which we have not been able to con-
firm blinding of outcome assessment with the authors. Overall,
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this review did not detect any significant likelihood of systematic
bias related to blinding in the included studies.
Incomplete outcome data
Loss to follow-up, usually due to failure to attend appointments,
or due to illness, was a significant problem for many of the in-
cluded studies. Of the 26 included studies, only eight had docu-
mented completion rates of 80% or more (Arnon 2009; Barclay
1991; Berglund 2010; Griffin 1999; Gross 1985; Jansson 1979;
Sankar 2009; Steinmacher 2007). Documentation of the recruit-
ment rate of eligible subjects was lacking from all the included
studies except Arnon 2009 and Sankar 2009. A number of studies
implied complete follow-up without explicitly stating the number
enrolled (Ferlin 1998;Groh-Wargo 1990;Halliday 1983;Melnick
1988). While the follow-up was suboptimal in most studies, this
review did not detect any significant likelihood of systematic bias
in attrition in the included studies.
Selective reporting
If any unpublished data had been received, we would have made
an assessment as to the existence of reporting bias in this topic.
As we did not receive any unpublished data, there is currently no
evidence of reporting biases.
Effects of interventions
Comparison 1: Enteral iron supplementation versus no iron
supplementation
Primary outcomes
• Neurodevelopmental outcome
None of the trials reported the neurodevelopmental outcome of
the participants.
• Growth
Thirteen trials reported at least one of the growth parameters
(weight, length or head circumference) as an outcome, but of-
ten without providing the numerical data. The duration of fol-
low-up varied from just six weeks postnatal age (Berseth 2004;
Melnick 1988), up to 18 months (Gorten 1964). Most trials only
monitored growth outcomes until about two months postnatal
age. Twelve studies did not find a statistically significant differ-
ence in weight gain between the groups (Aggarwal 2005; Barclay
1991; Berglund 2010; Berseth 2004; Coles 1954; Ferlin 1998;
Gorten 1964;Hall 1993;Melhorn1971;Melnick 1988;Quilligan
1954; Sankar 2009). None of the six trials that assessed linear and
head growth found a significant difference between the groups
(Aggarwal 2005; Barclay 1991; Berseth 2004; Ferlin 1998;Gorten
1964; Hall 1993).
One study found a difference in weight gain between the iron-
treated group and the untreated group. Reedy 1952 reported that
the treated infants with birth weight 1000 g to 1500 g had a greater
weight gain than the controls at 12months (mean difference (MD)
1.4 kg; no significance measure was provided). A smaller trend in
the same direction was seen in the 1500 g to 2000 g group (MD
794 g; no significance statistic), and the 2000 g to 2250 g group
(MD 1.4 kg; no significance statistic). The data from Reedy 1952
is severely limited by the small sample analysed at 12 months (four
treated and two untreated patients). We could not conduct ameta-
analysis of the growth outcomes due to a lack of appropriately
detailed numerical data (i.e. to enable calculation of means and
standard deviations (SDs)).
Secondary outcomes
• Blood haemoglobin concentration and mean corpuscular
volume (MCV)
Six to eight weeks: a total of 16 trials reported haemoglobin with
or without MCV at approximately six to eight weeks postnatal
(Barclay 1991; Coles 1954; Diamond 1958; Ferlin 1998; Franz
2000; Gorten 1964; Griffin 1999; Hall 1993; Halliday 1983;
Lundstrom 1977; Melhorn 1971; Melnick 1988; Quilligan 1954;
Reedy 1952; Rudolph 1981; Sankar 2009). Only Quilligan 1954
andGorten 1964 reported a significant benefit for the iron supple-
mentation group. Melhorn 1971 found a lower haemoglobin in
the iron supplementation group which was maximal at six weeks
(MD 6 g/L in 1000 g to 1500 g birth weight; MD 7 g/L in 1501
g to 2000 g birth weight; P < 0.01 for both). This apparent effect
of iron was ameliorated by supplementation with vitamin E.
Only nine trials (n =526) haddatawhichwere able to be pooled for
meta-analysis (Barclay 1991; Ferlin 1998; Gorten 1964; Griffin
1999; Hall 1993;Melhorn 1971; Quilligan 1954; Rudolph 1981;
Sankar 2009). On meta-analysis, there was no statistically signif-
icant difference in haemoglobin concentration: (WMD 1.4 g/L;
95% CI -0.2 to 3.1) (Outcome 1.4). The lack of a statistically
significant difference in haemoglobin concentration at six to eight
weeks remained in subgroup meta-analyses of trials of formula-fed
infants (n = 389) (WMD 0.7 g/L; 95% CI -1.1 to 2.6). In trials
of partially or fully breast fed babies (n = 137) a statistically sig-
nificant difference in favour of iron supplementation was noted:
(WMD4.1 g/L; 95%CI 0.6 to 7.7). However, there was statistical
heterogeneity in all meta-analyses, most likely due to differences
in the participants between the trials. For example, Barclay 1991
included term and preterm infants, while the other studies only
included preterm infants.
Three to four months : a total of 11 trials reported haemoglo-
bin with or without MCV at approximately three to four months
postnatal (Aggarwal 2005; Barclay 1991; Coles 1954; Diamond
1958; Gorten 1964; Griffin 1999; Hall 1993; Halliday 1983;
8Enteral iron supplementation in preterm and low birth weight infants (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Hanninen 1961; Lundstrom 1977; Reedy 1952). Four trials re-
ported that iron supplementation resulted in a statistically signif-
icant higher haemoglobin concentration (Aggarwal 2005; Coles
1954; Hanninen 1961; Lundstrom 1977). Data from five trials
were able to be pooled (Aggarwal 2005; Barclay 1991; Gorten
1964; Griffin 1999; Hall 1993). Meta-analysis found a borderline
statistically significant difference in haemoglobin concentration
(WMD 2.5 g/L; 95% CI -0.04 to 4.95) (Outcome 1.5). There
were no statistically significant differences in subgroup meta-anal-
yses of trials in formula-fed (WMD 2.4 g/L; 95% CI -0.42 to 5.2)
or breast fed infants (WMD 2.7 g/L; 95% CI -2.7 to 8.1). There
was statistical heterogeneity in all meta-analyses.
Six to nine months : a total of nine trials reported haemoglobin
with or without MCV at approximately six to nine months post-
natal (Berglund 2010; Coles 1954; Diamond 1958; Gorten 1964;
Griffin 1999; Halliday 1983; Hanninen 1961; Lundstrom 1977;
Reedy 1952). Six trials (Berglund 2010; Coles 1954;Gorten1964;
Hanninen 1961; Lundstrom 1977; Reedy 1952) reported a higher
haemoglobin in the iron supplementation group at six months;
Diamond 1958, Griffin 1999 and Halliday 1983 found no statis-
tically significant difference. Gorten 1964 and Griffin 1999 had
data available to pool. Both these studies were of formula-fed ba-
bies. Meta-analysis showed a statistically significantly higher hae-
moglobin concentration in the iron supplemented group (WMD
6.6 g/L; 95% CI 3.1 to 10.1) (Outcome 1.6.1), but with signifi-
cant heterogeneity between the trial estimates of effect. Berglund
2010 was a good quality study that found higher haemoglobin
when compared to placebo for both 2 mg/kg/day of elemental
iron (MD 8.0g/L; 95% CI 5.2 to 10.8) (Outcome 1.6.2) and 1
mg/kg/day of elemental iron (MD 3.8 g/L; 95% CI 1.2 to 6.4)
(Outcome 1.6.3).
Twelve months : a total of three trials reported haemoglobin
with or without MCV at approximately 12 months postnatal
(Gorten 1964; Halliday 1983; Reedy 1952). Gorten 1964 re-
ported a statistically significant difference in haemoglobin concen-
tration (WMD 16.0 g/L; 95% CI 10.7 to 21.3) (Outcome 1.7).
Halliday 1983 did not find a statistically significant difference.
Although Reedy 1952 reported a large difference in haemoglobin
between the iron supplementation and no iron supplementation
groups (MD 59 g/L in the 1000 g to 1500 g group), the finding
should be interpreted with caution due to extremely significant
loss to follow-up (n = 6 at 12 months in this birth weight group,
but n = 16 at birth).
MCV was reported as an outcome by Berglund 2010, Hall 1993
and Lundstrom 1977, but not by the other studies. At six to eight
weeks, Lundstrom 1977 found no significant difference in MCV,
but at three to four months (P < 0.01) and six to nine months (P <
0.05) there was a statistically significant difference in favour of the
iron supplementation group (the resultswere presented graphically
rather than numerically). Berglund 2010 also found an increase in
MCV compared to placebo at six months for both 2 mg/kg/day
of iron (MD 2.5 fL; 95% CI 1.3 to 3.7) (Outcome 1.11.1) and 1
mg/kg/day (MD 1.7 fL; 95% CI 0.5 to 2.9) (Outcome 1.11.2).
At six to eight weeks, Hall 1993 found a higher MCV in the iron
supplementation group (MD 4 fL; P < 0.05) and likewise at three
to four months (MD 6 fL; P < 0.01).
• Serum ferritin concentration, transferrin saturation, total
iron binding capacity (TIBC)
Six to eight weeks : (eight trials: Barclay 1991; Franz 2000; Griffin
1999;Hall 1993;Halliday 1983; Lundstrom1977;Melnick 1988;
Sankar 2009). Three trials reported a higher ferritin level in
the iron supplementation group (Hall 1993; Lundstrom 1977;
Melnick 1988). The other trials did not find any statistically sig-
nificant difference. Data on serum ferritin concentration suitable
for pooling was reported by Barclay 1991 and Hall 1993. Meta-
analysis did not detect a statistically significant difference (WMD
26.9 mcg/L; 95% CI -0.83 to 54.6 mcg/L).
Three trials reported the transferrin saturation at six to eight weeks.
Only Hall 1993 reported a statistically significantly difference
(MD 7.00%; 95% CI 0.05% to 13.95%) (Outcome 1.12) in
favour of iron supplementation.
Three to four months : data on serum ferritin concentration at
three to four months postnatal and suitable for pooling was pro-
vided by Aggarwal 2005, Barclay 1991 andHall 1993. The pooled
results showed a very small benefit in favour of the no iron sup-
plementation group (WMD -4.14 mcg/L; 95% CI -5.9 to -2.38).
A higher ferritin level at three to four months postnatal in the
iron supplementation group was found by Lundstrom 1977. No
difference in ferritin at three to four months was found by Griffin
1999 and Halliday 1983.
Two trials reported the transferrin saturation at two to four
months. Hall 1993 did not detect a statistically significantly dif-
ference (MD -4.00%; 95% CI -9.21 to 1.21) (Outcome 1.13).
Halliday 1983 found no difference at three to four months (MD
1% in favour of no iron supplementation, no significance calcu-
lation).
Six to nine months : (three trials: Berglund 2010; Griffin 1999;
Halliday 1983). Neither Griffin 1999 nor Halliday 1983 found a
statistically significant difference in serum ferritin levels. Halliday
1983 reported the data graphically, as did Griffin 1999. Berglund
2010 found a higher serum ferritin at six months compared with
placebo for both 2 mg/kg/day elemental iron (MD 30.7 mcg/L;
95% CI 30.0 to 31.4) (Outcome 1.10.1) and 1 mg/kg/day (MD
15.4 mcg/L; 95% CI 14.8 to 16.0) (Outcome 1.10.2).
Halliday 1983 reported transferrin saturation at six to nine
months, finding no difference (MD 1% in favour of no iron sup-
plementation, no significance calculation). Berglund 2010 found
a difference in favour of both 2 mg/kg/day of iron (MD 9.1%;
95% CI 6.0 to 12.2) (Outcome 1.14.1) and 1 mg/kg/day of iron
(MD 5.9%; 95% CI 3.4 to 8.4) (Outcome 1.14.2).
Twelve months : (one trial: Halliday 1983). Halliday 1983 did
not find a statistically significant difference in serum ferritin levels
(data presented graphically rather than numerically).
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Only Halliday 1983 reported transferrin saturation at 12 months,
finding no significant difference (MD 4% in favour of no iron
supplementation; no significance calculation).
No trials reported TIBC.
• Severe anaemia (haemoglobin level < 8 g/dL or hematocrit
level < 0.25)
Three studies reported the development of anaemia as an outcome
measure (Coles 1954; Gorten 1964; Hall 1993). However, only
Coles 1954 used a definition which was within the prespecified
range of < 8 g/dL; Gorten 1964 defined anaemia as haemoglobin
concentration below 9.0 g/dL on two successive tests; and Hall
1993 assessed as an outcome the prevalence of a haemoglobin
concentration < 9.0 g/dL at discharge from hospital. Therefore,
we did not pool the results for further analysis.
Coles 1954 defined anaemia as haemoglobin concentration below
7 g/dL once (or less than 7.5 g/dL for two consecutive months).
No infants (out of 22) in the iron supplementation group devel-
oped anaemia, but 3 of 29 in the no iron supplementation group
developed anaemia.
• Mortality: not reported by any trials.
• Chronic lung disease (one trial): Sankar 2009 did not find a
statistically significant difference (one occurrence in each group).
• Retinopathy of prematurity (one trial): Sankar 2009 did
not find a statistically significant difference.
• Necrotising enterocolitis (two trials): neither Berseth 2004
nor Sankar 2009 found a statistically significant difference in the
incidence of NEC.
• Invasive infection (two trials): neither Berseth 2004 nor
Sankar 2009 found a statistically significant difference in the
incidence of sepsis.
• Enteral feed intolerance (four trials: Aggarwal 2005;
Berseth 2004; Franz 2000; Melnick 1988).None of the trials
reported a statistically significant difference in the incidence of
feed intolerance. Aggarwal 2005 reported vomiting in 6% of the
iron supplementation group and 0% of the no iron
supplementation group at three to four months. Berseth 2004
compared a number of related outcomes (daily residuals,
abdominal distention, guaiac-positive stools, withholding of
feeds due to intolerance and clinically significant emesis) and
there were no statistically significant differences on any measure.
Franz 2000 reported a 16% incidence of feed intolerance in the
iron supplementation group, which was said to be similar to that
in the no iron supplementation group. Melnick 1988 did not
provide numerical data.
• Total duration of primary hospitalisation: not reported by
any trials.
• Requirement for readmission to hospital in the first year of
life (1 trial): Sankar 2009 found no significant difference in
rehospitalisation rate.
Subgroup analyses
Type of milk feeding : trials involving exclusively formula-fed in-
fants and those involving exclusively or partially breast fed infants:
details provided above.
Postnatal age of commencement of iron supplementation : ’early
commencement’ (less than 28 days postnatal) and ’late com-
mencement’ (28 days or more postnatal). Of the 21 studies, only
Aggarwal 2005, Berglund 2010, Coles 1954 and Griffin 1999 had
a ’late commencement’ of iron supplementation. Diamond 1958
and Reedy 1952 did not state the time of commencement. The
other 15 studies commenced ’early’. Quantitative meta-analysis of
haemoglobin at six to eight weeks: ’early commencement’ (WMD
1.55 g/L; 95% CI -0.12 to 3.2), ’late commencement’ (WMD -
1.1 g/L; 95% CI -8.8 to 6.6) (Outcome 1.16.4); and haemoglo-
bin at three to four months: ’early’ (WMD 0.75 g/L; 95% CI -2.4
to 3.9) (Outcome 1.17.3), ’late’ (WMD 5.6 g/L; 95% CI 1.4 to
9.8) (Outcome 1.17.4).
Daily dose of supplemental iron administered : ’low dose’ (2
mg/kg/day or less) and ’high dose’ (more than 2 mg/kg/day). The
studies using a low dose of iron were Berglund 2010 (including
doses of both 2 mg/kg/day and 1mg/kg/day), Franz 2000, Gorten
1964, Griffin 1999, Gross 1985, Lundstrom 1977 and Rudolph
1981. Reedy 1952 gave a low dose until discharge, followed by a
high dose; the other studies used a high dose. Quantitative meta-
analysis of haemoglobin at six to eightweeks: ’lowdose’ (WMD3.9
g/L; 95% CI 1.5 to 6.3) (Outcome 1.16.5), ’high dose’ (WMD
-0.76 g/L; 95% CI -3.0 to 1.5) (Outcome 1.16.6); and haemo-
globin at three to four months: ’low dose’ (WMD 4.0 g/L; 95%
CI 0.85 to 7.2) (Outcome 1.17.5), ’high dose’ (WMD -0.15 g/
L; 95% CI -4.2 to 3.9) (Outcome 1.17.6).
Duration of iron supplementation : ’short duration’ (six months
or less) and ’long duration’ (more than six months). Two studies
only administered iron for a short period, Coles 1954 ceasing
at eight weeks and Melhorn 1971 at six weeks. No numerical
data was available for quantitative meta-analysis after six to eight
weeks. Two other studies contained a comparison group ceasing
iron early (Griffin 1999 and Reedy 1952) - see Characteristics of
included studies tables for description. The remaining 15 studies
continued iron supplementation until at least the final outcome
measurement.
Gestational age or birth weight of participants, or both : less
than or equal to 33 completed weeks’ or less than 1500 g and more
than 33 completed weeks’ or 1500 g or more. Only two studies
dealt specifically with low birth weight infants (Aggarwal 2005
term LBW infants and Berglund 2010 marginally LBW infants,
irrespective of gestation). For a number of studies, mean birth
weights could not be obtained, but a reasonable estimate could be
made from the provided data. Studies in which the infants had
a published or estimated mean birth weight of less than 1500 g
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were Berseth 2004, Ferlin 1998, Franz 2000, Griffin 1999, Gross
1985, Hall 1993,Melnick 1988, Rudolph 1981 and Sankar 2009.
Studies with a published or estimated mean birth weight of over
1500 g were Aggarwal 2005, Barclay 1991, Coles 1954, Gorten
1964,Halliday 1983, Lundstrom 1977.Melhorn 1971 and Reedy
1952. Three studies did not provide enough information to es-
timate the mean birth weight (Diamond 1958; Hanninen 1961;
Quilligan 1954). On quantitative meta-analysis for haemoglobin
at six to eight weeks (8 trials), neither subgroup showed a signifi-
cant difference: ’under 1500 g’ (WMD -0.42 g/L; 95% CI -4.3 to
3.4) (Outcome 1.16.7); ’1500 g or over’ (WMD 0.77 g/L; 95%
CI -1.2 to 2.7) (Outcome 1.16.8). At three to four months (5
trials), the ’1500 g or over’ subgroup had a slight but statistically
significant benefit for haemoglobin in favour of iron supplemen-
tation: (WMD 3.5 g/L; 95% CI 0.3 to 6.8) (Outcome 1.17.8).
However, the ’under 1500 g’ subgroup had no significant differ-
ence: (WMD 1.0 g/L; 95% CI -2.9 to 4.8) (Outcome 1.17.7).
We could not perform subgroup analyses at later ages than three
to four months and for outcomes other than haemoglobin due to
the small number of studies with available data.
Comparison 2: Early versus late commencement of iron
supplementation - different regimens of iron
supplementation (dose, duration and timing of initiation)
(4 trials: Arnon 2009; Halliday 1983; Jansson 1979; Steinmacher
2007).
Primary outcomes
• Neurodevelopmental outcome
Steinmacher 2007 reported neurodevelopmental outcome at five
years of age; there was no significant difference in cognitive func-
tion testing at five years of age. There was an increased proportion
of children with abnormal clinical neurological examination in the
late iron group (35% versus 17%; P = 0.02).
• Growth
Steinmacher 2007 reported no significant difference in weight,
length and head circumference at five years of age.
Secondary outcomes
• Blood haemoglobin concentration and MCV (three trials:
Arnon 2009; Halliday 1983; Jansson 1979).
Six to eight weeks: we pooled data from Arnon 2009 and Jansson
1979. Haemoglobin concentration was higher in the early iron
group: (WMD 1.7 g/L; 95% CI 1.4 to 2.0). Halliday 1983 re-
ported that there was not a statistically significant difference in
haemoglobin concentration between the early and late supplemen-
tation groups, but the data were presented graphically rather than
numerically.
Three to four months : Jansson 1979 did not report at three to four
months. Halliday 1983 reported that there was not a statistically
significant difference in haemoglobin concentration between the
early and late supplementation groups, but numerical data were
not supplied.
Six to nine months : Jansson 1979 did not detect a statistically sig-
nificant difference in the haemoglobin concentration: (WMD0 g/
L; 95%CI -5.43 to 5.43) (Outcome 2.3). Halliday 1983 reported
that there was not a statistically significant difference in haemo-
globin concentration between the early and late supplementation
groups, but numerical data were not supplied.
Twelve months : Jansson 1979 did not report at 12 months.
Halliday 1983 reported that there was not a statistically significant
difference in haemoglobin concentration between the early and
late supplementation groups, but numerical data were not sup-
plied. Neither study reported MCV.
• Serum ferritin concentration, transferrin saturation, TIBC
(3 trials: Arnon 2009; Halliday 1983; Jansson 1979).
Six to eight weeks : Arnon 2009 found a higher serum ferritin in
the early iron group (WMD 25.0 mcg/L; 95% CI 16.9 to 33.1)
(Outcome 2.4). Jansson 1979 found no statistically significant
difference in serum ferritin (MD -16mcg/L; no significance calcu-
lation due to unreported SD). Halliday 1983 reported that there
was no statistically significant difference in transferrin saturation,
but numerical data were not supplied. Therefore, we were unable
to pool the data.
Three to four months : Jansson 1979 did not report at three to
fourmonths. Halliday 1983 reported that there was no statistically
significant difference in transferrin saturation, but numerical data
were not supplied.
Six to nine months : Jansson 1979 found no statistically signifi-
cant difference in serum ferritin (MD -2 mcg/L; no significance
calculation). Halliday 1983 reported that there was no statistically
significant difference in transferrin saturation, but numerical data
were not supplied.
Twelve months : Jansson 1979 did not report at 12 months.
Halliday 1983 reported that there was no statistically significant
difference in transferrin saturation, but numerical data were not
supplied.
• Severe anaemia: not reported by any trials.
• Mortality: not reported by any trials.
• Chronic lung disease: no difference (Arnon 2009).
• Retinopathy of prematurity: no difference (Arnon 2009).
• Necrotising enterocolitis: no difference (Arnon 2009).
• Invasive infection: no difference (Arnon 2009).
• Enteral feed intolerance: not reported by any trials.
• Total duration of primary hospitalisation: not reported by
any trials.
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• Requirement for readmission to hospital in the first year of
life: not reported by any trials.
Comparison 3: High versus low dose iron supplementation
(Three trials: Barclay 1991; Friel 2001; Groh-Wargo 1990).
Primary outcomes
• Neurodevelopmental outcome (one trial)
Friel 2001 did not find a statistically significant difference in the
Griffiths Developmental Assessment score at 12 months: 118 in
both groups (WMD 0.000; 95% CI -6.38 to 6.38) (Outcome
3.1).
• Growth (three trials)
None of the trials found any statistically significant differences in
growth parameters up to about 20 weeks postnatal age. Numerical
data were only provided by Friel 2001, who documented no signif-
icant difference in weight and height z scores at approximately 12
months postnatally (z score difference of 0 and 0.1 respectively).
Secondary outcomes
• Blood haemoglobin concentration and MCV
Six to eight weeks : (two trials: Barclay 1991; Friel 2001).
(Groh-Wargo 1990 did not supply data for six to eight weeks).
Neither individual trial, nor meta-analysis of both trials, found
a statistically significant difference between the groups: (WMD -
1.4 g/L; 95% confidence interval -8.2 to 5.4) (Outcome 3.2.1).
Three to four months : (two trials: Barclay 1991; Friel 2001;Groh-
Wargo 1990). None of the individual trials found a statistically
significant difference between the groups. However, meta-analysis
suggested a slight benefit in favour of the higher iron dose: (WMD
4.49 g/L; 95% CI 0.84 to 8.13) (Outcome 3.3). Groh-Wargo
1990 reported that the MCV was statistically significantly higher
in the high dose group: (WMD 3.30 units; 95% CI 0.06 to 6.54)
(Outcome 3.6).
Six to nine months: (one trial: Friel 2001). The trial did not find
a statistically significant difference in mean haemoglobin concen-
tration between the groups: (MD 4.0 g/L; 95% CI -1.6 to 9.6)
(Outcome 3.4).
Twelve months : (one trial Friel 2001). The trial did not find a
statistically significant difference between the groups: (MD -2.0
g/L; (95% CI -7.2 to 3.2) (Outcome 3.5).
• Serum ferritin concentration, transferrin saturation, TIBC
(two trials: Friel 2001; Groh-Wargo 1990).
Six to eight weeks : Friel 2001 did not detect a statistically signif-
icant difference in ferritin concentration between the two groups:
(MD -5.00; 95% CI -33.1 to 23.1) (Outcome 3.7). The transfer-
rin saturation level was statistically significantly lower in the high
dose group: (MD -10.0%; 95% CI -17.7 to -2.27) (Outcome
3.11).
Three to four months : neither study detected a statistically
significant difference in ferritin concentration. On meta-analy-
sis, (WMD 4.2; 95% CI -3.7 to 12.0). Neither Friel 2001 nor
Groh-Wargo 1990 found a significant difference in transferrin
saturation: on meta-analysis, (WMD 1.74; 95% CI -1.2 to 4.7)
(Outcome 3.12).
Six to nine months : Friel 2001 reported a statistically signifi-
cant higher mean ferritin concentration in the high dose group:
(MD 4.00; 95% CI 0.12 to 7.88) (Outcome 3.9). The transferrin
saturation level was not statistically significantly different: (MD
2.00%; 95% CI -2.95 to 6.95) (Outcome 3.13).
Twelve months : Friel 2001 did not detect a statistically significant
difference in ferritin concentration (MD -2.00; 95% CI -7.67 to
3.67) (Outcome 3.10).
• Severe anaemia: not reported by any trials.
• Mortality: not reported by any trials.
• Chronic lung disease: not reported by any trials.
• Retinopathy of prematurity: not reported by any trials.
• Necrotising enterocolitis: not reported by any trials.
• Invasive infection: not reported by any trials.
• Enteral feed intolerance: not reported by any trials.
• Total duration of primary hospitalisation: not reported by
any trials.
• Requirement for readmission to hospital in the first year of
life: not reported by any trials.
Comparison 4: Duration of iron supplementation
(Two trials: Griffin 1999 and Reedy 1952)
• Blood haemoglobin concentration and MCV
Six to eight weeks : Griffin 1999 found no difference in haemo-
globin (MD 3.7; 95% CI -3.8 to 11.2) (Outcome 4.1). Reedy
1952 found aMD of 6 g/L in favour of short duration in the 1000
g to 1500 g group (no significance calculation possible), and 3 g/
L in favour of short duration in the 1500 g to 2000 g group (no
comparison available for the 2000 g to 2250 g group). This result
is severely limited by the large loss to follow-up.
Three to four months : Griffin 1999 found no difference in hae-
moglobin (MD 1.5 g/L; 95% CI -3.9 to 6.9 g/L) (Outcome 4.2).
Reedy 1952 found a MD of 10 g/L in favour of long duration in
the 1000 g to1500 g group (no significance calculation possible),
but no difference in the larger birth weight groups. This result is
severely limited by the large loss to follow-up.
Six to nine months : Griffin 1999 found a slight benefit for the
longer duration of iron supplementation (MD 5.7 g/L; 95% CI
0.5 to 10.9) (Outcome 4.3). Reedy 1952 found a MD of 5 g/
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L in favour of short duration in the 1000 g to 1500 g group (no
significance calculation possible), 2 g/L in favour of long duration
in the 1500 g to 2000 g group and 3 g/L in favour of short duration
in the 2000 g to 2250 g group. The results of Reedy 1952 are
severely limited by the large loss to follow-up.
Twelve months : Reedy 1952 found a MD of 28 g/L in the 1000
g to 1500 g group (no significance calculation possible), and of
10 g/L in the 2000 g to 2250 g group (no comparison available
for the 1501 g to 2000 g group). The results of Reedy 1952 are
severely limited by the large loss to follow-up.
See Table 1 for summary of results by study.
D I S C U S S I O N
Summary of main results
There is insufficient evidence regarding the effect of enteral
iron supplementation on the neurodevelopmental and long term
growth outcomes for preterm and low birth weight infants. No
RCT comparing enteral iron supplementation with no iron sup-
plementation examined the comparative neurodevelopmental out-
comes.
Enteral iron supplementation of both preterm and term low birth
weight infants appears to confer a slight improvement in haemo-
globin and ferritin levels after eight weeks postnatal age, and re-
duces the risk of infants developing anaemia. However, there is
significant heterogeneity in the outcomes of the included RCTs,
which is likely due to a number of methodological issues outlined
below.
This review did not identify any benefit in providing more than
2 mg/kg/day to 3 mg/kg/day of elemental iron. Some recent evi-
dence supports provision of iron supplementation to all low birth
weight infants, whether they are born term or preterm (Berglund
2010).
Overall completeness and applicability of
evidence
One study compared early commencement of iron supplementa-
tion with later commencement, finding no difference in cognitive
development at five years of age, but an increase in the rate of ab-
normal clinical neurological examination in the late commence-
ment group (Steinmacher 2007). One further study comparing a
standard dose of iron supplementation with a higher dose exam-
ined the neurodevelopmental outcome of infants, and did not find
any difference up to 12 months of age (Friel 2001). A number of
studies measured weight and/or length and head circumference,
but in all cases this was only done for the duration of monitor-
ing of haematological parameters, which for most studies was well
under a year postnatally.
Most studies were concerned primarily with assessing the effects of
iron supplementation on haematological parameters such as hae-
moglobin and serum ferritin levels. However, only a small num-
ber of studies were able to be quantitatively synthesised, because
appropriate data was not available, despite attempting to contact
the authors for further data. The studies included were very het-
erogeneous, in relation to the population, the intervention used,
the outcomes measured and the results themselves. Qualitatively,
the evidence to date indicates that the provision of enteral iron
supplementation to premature and term, low birth weight infants
probably confers a slight benefit for the haemoglobin level from
approximately two months postnatally. Iron stores, reflected in the
serum ferritin, are also slightly benefited by iron supplementation.
One recent, relatively large RCT has suggested that an early (two
weeks postnatal) commencement of iron supplementation results
in improved haematological parameters compared with later (four
weeks) introduction of iron (Arnon 2009).
Quality of the evidence
The methodological quality of most of the RCTs was fair at best.
For example, only eight of the 26 studies are known to have used
allocation concealment of adequate quality. Most failed to report
adequate blinding of intervention and outcome measurement,
and only eight of 26 had documented follow-up rates of more
than 80% for the key outcomes at the end of the study. Other
methodological weaknesses were contamination of non iron-sup-
plemented groups by iron-fortified formulas (Barclay 1991; Franz
2000; Jansson 1979) and removal of anaemic infants from analy-
sis (Coles 1954; Gorten 1964; Lundstrom 1977; Melhorn 1971).
Since most of these removals came from the control (unsupple-
mented) groups, this is likely to have resulted in an underestima-
tion of the effect of iron supplementation on haemoglobin levels.
There was also a paucity of outcome data reported for possible
morbidity associated with iron supplementation, such as necrotis-
ing enterocolitis, retinopathy of prematurity, and chronic neonatal
lung disease. Rather, the studies looking at adverse effects of iron
supplementation concentrated on haematological measures such
as evidence of red cell fragility or haemolysis.
Of the studies comparing enteral iron supplementation versus no
iron supplementation, there was some variation in the doses of
iron administered. The most common dose of iron (either as a
medicinal supplement or as formula fortification)was 2mg/kg/day
to 3mg/kg/day of elemental iron, whichwas the dose administered
in 11of those 21 studies. This review didnot find any evidence that
a dose greater than that recommended by the AAP (2 mg/kg/day)
results in improvement of outcomes. This is reflected both in the
results of studies that specifically addressed this question (Barclay
1991; Friel 2001; Groh-Wargo 1990) and in the subgroup analysis
of trials using doses of iron of 2 mg/kg/day or less compared with
those using a higher dose,meta-analysis ofwhich actually indicated
a small but statistically significant benefit for haemoglobin at six
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to eight weeks and three to four months in the ’low iron’ but not
the ’high iron’ group.
A few features of the heterogeneity of study methods are worthy of
further comment. First, studies varied greatly in their approach to
blood transfusion. For example, among the 21 studies comparing
enteral iron supplementation with no (or minimal) iron supple-
mentation, four permitted blood transfusions among the partic-
ipants before and during the study period (Berseth 2004; Franz
2000; Hall 1993; Sankar 2009). Two studies permitted trans-
fusions before, but not after study entry (Barclay 1991; Griffin
1999). The other studies either excluded all infants who required
transfusion (7 studies), or did not state any policy (eight studies).
The effect of this heterogeneity could be important, given the iron
content of blood, and previous research which has suggested that
premature babies who receive multiple transfusions are at risk of
iron overload (Ng 2001). It is feasible that extremely preterm in-
fants who receive one or more blood transfusions may not receive
as much benefit from iron supplementation as more mature in-
fants who do not receive any transfusions (Ng 2001; Rao 2002).
One author suggests that the measurement of ferritin levels in
preterm neonates who have received transfusions may be useful to
guide the initiation of iron therapy, but again this remains untested
(Brown 1996). Of the nine studies comparing iron with no iron
that were known or estimated to have a mean birth weight of less
than 1500 g (Aggarwal 2005; Berseth 2004; Ferlin 1998; Franz
2000; Griffin 1999; Hall 1993; Melnick 1988; Rudolph 1981;
Sankar 2009), five of these studies Berseth 2004; Franz 2000;
Griffin 1999; Hall 1993; Sankar 2009) included infants who had
received blood transfusions prior to commencement of the inter-
vention and two studies did not state the policy on transfusions
(Melnick 1988; Rudolph 1981).
Second, the provision or otherwise of vitamin E supplementation
varied between the studies. Apart from the two studies which in-
vestigated the supplementation of vitamin E as a controlled inter-
vention (Ferlin 1998; Melhorn 1971), five other studies reported
vitamin E supplementation of both the intervention and control
groups, ranging from 2 IU/kg/day to 20 IU/kg/day (Barclay 1991;
Berseth 2004; Gross 1985; Lundstrom 1977; Rudolph 1981;
Sankar 2009). The heterogeneity and uncertainty around the pro-
vision or otherwise of vitamin E in these studies is unlikely to have
resulted in a significant adverse impact on the review’s validity. For
example, the finding byMelhorn 1971 that iron supplementation
exacerbates the ’early’ anaemia of prematurity (i.e. at six to eight
weeks postnatally) was not supported by the other trials in this re-
view. In the studies in which the presence or absence of vitamin E
supplementation was not documented, it is unlikely, particularly
in the studies from the 1950s and 1960s, that it had been given.
In most modern neonatal units, a small vitamin E supplement is
routinely given to preterm infants, in accordance with AAP rec-
ommendations of 5 IU to 25 IU per day (AAP 1985). In Melhorn
1971, the apparent deleterious effect of iron supplementation was
ameliorated by vitamin E supplementation. Therefore, any resid-
ual concern that iron might exacerbate the early anaemia of preg-
nancy in non-vitamin E supplemented infants is unlikely to be
relevant today.
Third, the provision of enteral cobalt was examined in three stud-
ies from the 1950s. No clear picture of its utility for haematolog-
ical outcome emerged. The study by Coles 1954 suggested the
conferring of a slight benefit for haemoglobin level by the addition
of cobalt supplementation at two months, but this was smaller in
magnitude, duration and statistical significance than that given by
iron supplementation. The study of Diamond 1958 appeared to
show a slight benefit also, but was of poor quality. In Quilligan
1954 there was no comparison with iron alone, and so no conclu-
sion can be drawn about the additive effect of cobalt.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is a paucity of evidence from RCTs about how enteral iron
supplementation of preterm and low birth weight infants affects
growth and neurodevelopmental outcomes. However, there ap-
pear to be slight haematological benefits after eight weeks postna-
tal age. Doses of more than 2 mg/kg/day to 3 mg/kg/day of iron
do not appear to confer extra benefit. One recent trial suggests that
commencing iron early (at two weeks of age) results in improved
haematological parameters from as early as eight weeks of age. The
RCT evidence to date does not suggest a particular threshold of
birth weight or gestational age at which iron supplementation be-
comes beneficial, and two of the more recent and methodologi-
cally sound trials suggest a benefit even for marginally low birth
weight infants, whether term or preterm.
Implications for research
There is a need for new RCTs of enteral iron supplementation in
preterm infants that stratify according to birth weight and ges-
tation, feeding method (breast milk or formula) and prior blood
transfusion. This is because it remains unclear from RCT evidence
to date whether enteral iron supplementation is required, or in-
deed might cause harm, in the very low birth weight or extremely
low birth weight preterm infant who has already received a blood
transfusion. There are strong arguments on a physiological basis
that supplementation might only be required in non-transfused
infants, but this has not been satisfactorily tested to date.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Aggarwal 2005
Methods Blinding of randomisation: yes (author correspondence)
Blinding of intervention: yes
Complete follow-up: 4 weeks - yes (85%); 8 weeks - no (36%)
Blinding of outcome measurement: yes
Participants Gestation: term
Birth weight: low birth weight (< 2500 g)
Feeding: breast fed
Age of enrolment: 50 to 80 days
Exclusion criteria: twinning, congenital malformations, > 10 mL of blood sampling in
the past, those already on iron supplementation, significant morbidity and maternal
antepartum haemorrhage
Blood transfusions: excluded if previously received
Interventions Iron supplementation group: 3 mg/kg/day as ferric ammonium citrate drops (n = 37),
commencing at 50 to 80 days of age
No iron supplementation group: indistinguishable placebo mixture (n = 36)
Outcomes Primary: haemoglobin concentration
Secondary: peripheral smear, serum ferritin, weight, length, head circumference
Timing: baseline (7 to 11weeks postnatal), 4 weeks (11 to 15 weeks postnatal) and 8
weeks (15 to 19 weeks postnatal)
Notes 73 infants were randomised
Randomisation was performed using computer generated random numbers
Protocol for treatment of anaemia: not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generation
Allocation concealment (selection bias) Low risk Adequate allocation concealment (author
correspondence)
Blinding (performance bias and detection
bias)
All outcomes
Low risk Blinding of intervention: yes
Blinding of outcome measurement: yes
Incomplete outcome data (attrition bias)
All outcomes
High risk 8 week follow-up 36%
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Aggarwal 2005 (Continued)
Selective reporting (reporting bias) Unclear risk No evidence of selectivity
Other bias Low risk No other risk of bias identified
Arnon 2009
Methods Blinding of randomisation: unclear
Blinding of intervention: no (author communication)
Complete follow-up: Yes (87%)
Blinding of outcome measurement: Yes (author communication)
Participants Gestation: <= 32 weeks
Birth weight: no limits (mean < 1300 g)
Feeding: breast milk
Exclusion criteria:major anomalies, haemolytic disease, twin-twin transfusion syndrome,
illness requiring cessation of supplementation for over 3 days
Blood transfusions: permitted prior to study entry (when enteral intake >= 100 mL/
kg/day); excluded if requiring transfusion during study period. Restrictive transfusion
policy
Interventions Early iron group: Iron polymaltose complex, 5mg/kg/day, from 2 weeks of age
Late iron group: Iron polymaltose complex, 5mg/kg/day, from 4 weeks of age (after
receiving placebo from 2 weeks)
Both groups received 25 IU of vitamin E from 2 to 8 weeks of age
Outcomes Primary outcome: vitamin E (alpha-tocopherol) levels at 2, 4 and 8 weeks of age
Secondary outcomes: serum iron, serum ferritin, haemoglobin level and reticulocyte
count at 2, 4 and 8 weeks of age
Not published for full cohort, but received from author: requirement for transfusion and
soluble transfusion receptor level (at 2, 4 and 8 weeks of age)
Notes Requirement for transfusion and soluble transfusion receptor level (at 2, 4 and 8 weeks
of age) were also reported in Arnon 2007 in a subset of this cohort
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generation
Allocation concealment (selection bias) Unclear risk Allocation known to pharmacist but con-
cealed from treating staff using envelopes
(author communication)
Blinding (performance bias and detection
bias)
All outcomes
High risk Blinding of intervention: No (author com-
munication)
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Arnon 2009 (Continued)
Blinding of outcome measurement: Yes
(author communication)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Complete follow-up: Yes (87%)
Selective reporting (reporting bias) Unclear risk No evidence of selectivity
Other bias Low risk No other risk of bias identified
Barclay 1991
Methods Blinding of randomisation: not known
Blinding of intervention: not known
Complete follow-up: yes (89%)
Blinding of outcome measurement: not known
Participants Gestation: term or preterm
Birth weight: less than 2500 g
Feeding: 11 infants were exclusively fed breast milk, and the remainder received infant
formula containing 5 to 6.7 mg/l (0.8 mg/kg/day) of iron
Exclusion criteria: congenital or chromosomal abnormalities, haemolytic disease, gas-
trointestinal disorders and intravenous nutrition for more than 5 days
Blood transfusion: excluded if occurring after day 14
Interventions High iron group (HiFe): approximately 7.1 mg/kg/day (13.8 mg of iron daily as iron
edetate) (n = 20)
Low iron group (MidFe): approximately 3.6 mg/kg/day (7 mg iron daily as iron edetate)
(n = 16) (this group used as iron supplementation group for comparison with no iron
supplementation)
No iron supplementation group (NatFe): no additional iron (n = 19)
All supplements began at 28 days postnatally
Outcomes Primary: erythrocyte superoxide dismutase levels
Secondary: haemoglobin concentration, reticulocyte count; plasma copper, zinc and
ferritin levels; weight, length and head circumference
Timing: baseline (27 days), 8 weeks, 12 weeks and 20 weeks postnatal age
Notes 62 infants were randomised
Infants were randomised within each stratum of gestational age (< 32 weeks, 33 to 35
weeks and > 36 weeks)
The infants received different vitamin regimens based on their birth weight, which did
not necessarily correlate strictly with the gestational age groups
The data for those who failed to attend follow-up visits were not included in the analysis
Treatment of anaemia: not stated
Risk of bias
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Barclay 1991 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not stated
Allocation concealment (selection bias) Unclear risk Blinding of randomisation: not known
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Blinding of intervention: not known
Blinding of outcome measurement: not
known
Incomplete outcome data (attrition bias)
All outcomes
Low risk Complete follow-up: yes (89%)
Selective reporting (reporting bias) Unclear risk No known selectivity
Other bias Low risk No other risk of bias identified
Berglund 2010
Methods Blinding of randomisation: yes
Blinding of intervention: yes
Complete follow-up: yes (91%)
Blinding of outcome measure: yes
Participants Gestation: term or preterm, enrolment at 6 weeks postnatal age
Birth weight: 2000 g to 2500 g
Feeding: breast milk or iron-fortified formula
Exclusion criteria: disease symptoms at 6 weeks postnatal, chronic disease, previous
blood transfusion, previous iron supplementation and anaemia or other haematological
disorder at 6 weeks postnatal
Blood transfusions: excluded
Interventions High iron group (HiFe): 2 mg/kg/day of elemental iron (as ferrous succinate) from 6
weeks to 6 months postnatal age
Low iron group (MidFe): 1 mg/kg/day of elemental iron (as ferrous succinate) from 6
weeks to 6 months postnatal age
No iron group: placebo mixture from 6 weeks to 6 months postnatal age
Outcomes Haematological: at baseline (6 weeks), 12 weeks and 6 months - complete blood count,
haemoglobin level, mean cell volume, serum ferritin, serum transferrin, serum iron, C-
reactive protein, transferrin saturation, transferrin receptor concentration
Growth: at baseline (6 weeks), 12 weeks, 19 weeks and 6 months - weight, length, head
circumference, knee-heel length
Notes Infants were randomised within stratification for gender and study centre
Risk of bias
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Berglund 2010 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated randomisation
Allocation concealment (selection bias) Low risk Blinding of treatment assignment was re-
ported
Blinding (performance bias and detection
bias)
All outcomes
Low risk As reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk Follow up 91%
Selective reporting (reporting bias) Unclear risk No known selectivity
Other bias Low risk No other risk of bias identified
Berseth 2004
Methods Blinding of randomisation: yes (author communication)
Blinding of intervention: yes
Complete follow-up: no (52%)
Blinding of outcome measurement: yes
Participants Gestation: less than 33 weeks
Birth weight: less than 1500 g
Feeding: breast milk (fortified)
Exclusion criteria: conditions expected to affect growth or feed tolerance; 5-minute Apgar
score < 4; major surgery; IVH of grade 3 or 4; 4 or more days of steroid therapy before
or within 72 hours of day 0; had received any HMF before day 0; had received EPO,
vitamin D, minerals or iron by day 0; still mechanically ventilated by day 0
Blood transfusion: permitted
Interventions Iron supplementation group: approximately 2.4mg/kg/day of iron (in powdered fortifier
which providing 15.3 mg/L of iron (n = 96), commencing when enteral intake > 100
mL/kg/day
No iron supplementation group: approximately 0.64 mg/kg/day of iron (in another
fortifier providing 4.4 mg/L of iron (n = 85)
The first day of fortification was at half strength, and from the second day at full strength
Outcomes Primary outcome: weight gain
Secondary outcomes:
Length and head circumference; hematocrit, albumin, transthyretin, alkaline phos-
phatase, BUN, triglycerides, sodium, potassium, chloride, bicarbonate, calcium, phos-
phorus, magnesium, zinc, copper, ferritin and vitamin D
Incidence of feed intolerance (gastric residuals, abdominal distention and emesis), respi-
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Berseth 2004 (Continued)
ratory outcomes (supplemental oxygen, mechanical ventilation), and incidence of NEC.
Need for blood transfusion
Notes 185 infants were randomised
Infants were randomised when they had achieved an enteral intake of 100 ml/kg/day of
unfortified human milk
Randomisation occurredwithin predetermined stratification groups (by gender and birth
weight above or below 1000 g)
Blinding was achieved by otherwise identical, coded labels
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated (author communica-
tion)
Allocation concealment (selection bias) Low risk Blinding of randomisation: yes (author
communication).
Blinding (performance bias and detection
bias)
All outcomes
Low risk Blinding of intervention: yes
Blinding of outcome measurement: yes
Incomplete outcome data (attrition bias)
All outcomes
High risk 52% follow-up to completion
Selective reporting (reporting bias) Unclear risk No known selectivity
Other bias Low risk No other identified bias
Coles 1954
Methods Blinding of randomisation: not known
Blinding of intervention: not known
Complete follow-up: no (58.7% at 6 months)
Blinding of outcome measurement: not known
Participants Gestation: premature (specific gestation not specified)
Birth weight: not stated
Feeding: breast or formula fed
Exclusion criteria: severe haemorrhage, death
Blood transfusion policy: not stated
Interventions Iron supplementation group (Group IV): Approx 44 mg/kg/day of iron (as 4.5 grains of
ferrous sulphate) and cobalt sulphate 20 mg daily (n = 22) from 4 to 8 weeks of life
No iron supplementation group (Group III): Cobalt sulphate orally, 20 mg daily from
4 to 8 weeks (n = 29)
Other groups not included in systematic review:
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Coles 1954 (Continued)
Group I: controls (n = 53)
Group II: cobalt sulphate orally, 10 mg daily from day 1 to 12 of life (n = 22)
Outcomes Primary outcomes: haemoglobin concentration and red blood cell count
Timing: birth, 1 week, 2 weeks, 1 month, monthly to 6 months, at 9 months and 1 year
postnatal
Notes 51 infants were randomised to the groups included in this review (groups IV and III)
Iron and cobalt supplements or both were administered from 4 to 8 weeks postnatally
Management of anaemia: ferrous sulphate 4.5 grains (approximately 44 mg/kg/day)
when haemoglobin < 70 g/L (< 6 months), or < 75 g/L (> 6 months) and cobalt sulphate
20 mg if RCC < 2.5 m/cmm and haemoglobin < 70 g/L
Vitamin supplementation: vitamins A, D and C
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not stated
Allocation concealment (selection bias) Unclear risk Blinding of randomisation: not known
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Blinding of intervention: not known
Blinding of outcome measurement: not
known
Incomplete outcome data (attrition bias)
All outcomes
High risk Complete follow-up: no (58.7% at 6
months)
Selective reporting (reporting bias) Unclear risk No known selectivity
Other bias Low risk No other risk of bias identified
Diamond 1958
Methods Blinding of randomisation: no (quasi-randomised)
Blinding of intervention: not known
Complete follow-up: not known (100% implied)
Outcome assessment blind: not known
Participants Gestation: not stated
Birth weight: not stated
Feeding: not stated
Interventions Iron supplementation group (Group 2): approximately 12 mg/kg/day of iron (as 75 mg
per day of ferrous sulfate) (n = 12)
No iron supplementation group (Group 3): no supplement (n = 16)
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Diamond 1958 (Continued)
Time of commencement of supplementation is not stated
Additional study group not included in systematic review:
Group 1: approximately 12 mg/kg/day of iron (as 75 mg per day of ferrous sulfate) and
2 mg/kg/day of cobalt chloride (n = 16)
Outcomes Primary outcome: haemoglobin level
Timing of outcome measurement: monthly, up to 6 months postnatal
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quasi-randomised
Allocation concealment (selection bias) High risk Blinding of randomisation: no (quasi-ran-
domised)
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Blinding of intervention: not known
Outcome assessment blind: not known
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Complete follow-up: not known (100%
implied)
Selective reporting (reporting bias) Unclear risk No known selectivity
Other bias Low risk No other known bias
Ferlin 1998
Methods Blinding of randomisation: no (author communication - quasi-randomised)
Blinding of intervention: yes (placebo used)
Complete follow-up: not known (100% implied)
Blinding of outcome measurement: yes (author communication)
Participants Gestation: up to 35 weeks gestation
Birth weight: less than 1600 g birth weight
Feeding: all started on breast milk, then changed to a non-iron supplemented formula
at unspecified intervals
Exclusions: those who failed to attend follow-up
Blood transfusion policy: excluded from study
Interventions Iron supplementation group: iron supplementation of 4 mg/kg/day of iron (as ferrous
sulfate), with 25 IU/day of vitamin E supplementation (Group III, n = 10), or without
vitamin E supplementation (Group II, n = 10). Iron supplementation was commenced
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Ferlin 1998 (Continued)
on the 15th day of life
No iron supplementation group: placebo (Group I, n = 10) or 25 IU/day of vitamin E
supplementation (Group IV, n = 10)
Outcomes Primary: haemoglobin concentration and hematocrit
Secondary: weight, length and head circumference; reticulocytes, platelets and red cell
resistance to hydrogen peroxide
Timing: 24 to 72 hours of age and 2 months of age
Notes Although the infants included in the analysis were followed to completion of the study,
it is stated that regular attendance at follow-up appointments was a prerequisite for
inclusion in the study; it is not stated how many infants were initially randomised but
later excluded due to loss to follow-up or other prespecified events such as the need for
blood transfusion, or other ’interfering events’ that resulted in cessation of treatment
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quasi-randomised
Allocation concealment (selection bias) High risk Blinding of randomisation: no (author
communication - quasi-randomised)
Blinding (performance bias and detection
bias)
All outcomes
Low risk Blinding of intervention: yes (placebo
used)
Blinding of outcome measurement: yes
(author communication)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Complete follow-up: not known (100%
implied)
Selective reporting (reporting bias) Unclear risk No known selectivity
Other bias Low risk No other known bias
Franz 2000
Methods Blinding of randomisation: no (author communication)
Blinding of intervention: yes; but allocation became obvious due to stool colour
Complete follow-up: no (65%)
Blinding of outcome measurement: yes
Participants Gestation: no limit
Birth weight: less than 1301 g
Feeding: either breast fed or received an iron-fortified formula (12 mg/L, or approxi-
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Franz 2000 (Continued)
mately 1.9 mg/kg/day of iron)
Exclusion criteria: major anomalies, haemolytic disease and twin-to-twin transfusion
Blood transfusion policy: permitted, before and after entry; restrictive transfusion policy
Interventions Iron supplementation group: 2 mg/kg/day of iron as ferrous sulfate, commenced as soon
as enteral feedings were tolerated (n = 105)
No iron supplementation group: 2 mg/kg/day of iron as ferrous sulfate, commenced at
61 days of life (n = 99)
Management of anaemia: when the hematocrit level fell below 0.30, the dose of iron was
increased to 4 mg/kg/day. The policy for the administration of blood transfusions was
clearly outlined
Outcomes Primary outcome: serum ferritin and incidence of iron deficiency
Secondary outcomes: transferrin, transferrin saturation, serum iron, reticulocytes, hema-
tocrit; number of transfusions required and blood volume transfused
Timing: birth; at 1.6 times birth weight; at 61 days of life; and opportunistically when
the hematocrit level was < 0.25
Notes Randomised on day 7 of life. The infants either received breast milk or iron-fortified
formula (12 mg/L, approximately 1.9 mg/kg/day) The iron intake due to formula was
reported to be similar between the two groups
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated. Reported
in Steinmacher 2007 (continuation of this
study)
Allocation concealment (selection bias) High risk Blinding of randomisation: no (author
communication)
Blinding (performance bias and detection
bias)
All outcomes
Low risk Blinding of intervention: yes; but alloca-
tion became obvious due to stool colour
Blinding of outcome measurement: yes
Incomplete outcome data (attrition bias)
All outcomes
High risk Follow-up to completion: 65%
Selective reporting (reporting bias) Unclear risk No known selectivity
Other bias Low risk No other risk of bias identified
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Friel 2001
Methods Blinding of randomisation: yes (author communication)
Blinding of intervention: yes
Complete follow-up: no (72.4%)
Blinding of outcome measurement: yes
Participants Gestation: term or preterm
Birth weight: low birth weight (< 2500 g)
Feeding: formula
Exclusions: bronchopulmonary dysplasia, hydrocephalus, liver dysfunction or had con-
genital malformations
Blood transfusion policy: not stated
Interventions High iron group (HiFe): approximately 3.4 mg/kg/day of iron (in formula containing
21 mg/L of iron) (n = 29)
Low iron group (MidFe): approximately 2.1 mg/kg/day of iron (in formula containing
13.4 mg/L of iron) (n = 29)
Infants were assigned to groups at close to 2000 g weight and when on full oral feeds
Outcomes Primary outcomes: Griffith Developmental Assessment score (at 3, 6, 9 and 12 months
corrected), weight, and height. Haemoglobin level, hematocrit, ferritin, transferrin,
transferrin saturation, and plasma iron
Secondary outcomes: malondialdehyde level, plasma zinc and copper levels, red blood
cell fragility, catalase level, superoxide dismutase level and glutathione peroxidase level
Timing: baseline, discharge, and 3, 6, 9 and 12 months corrected age
Notes Randomisation was achieved using a random number table and concealed allocation was
performed using opaque sealed envelopes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number table (author communi-
cation)
Allocation concealment (selection bias) Low risk Blinding of randomisation: yes (author
communication)
Blinding (performance bias and detection
bias)
All outcomes
Low risk Blinding of intervention: yes
Blinding of outcome measurement: yes
Incomplete outcome data (attrition bias)
All outcomes
High risk Follow-up to completion: 72.4%
Selective reporting (reporting bias) Unclear risk No known selectivity
Other bias Low risk No other risk of bias identified
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Gorten 1964
Methods Blinding of randomisation: yes (sealed envelopes)
Blinding of intervention: yes
Complete follow-up: no (55.9% at 12 months)
Blinding of outcome measurement: yes
Participants Gestation: premature
Birth weight: mean birth weight was 1.84 kg (29.9 weeks gestation) in the study group;
and 1.89 kg (33.5 weeks gestation) in the control group
Feeding: formula
Blood transfusion policy: not stated
Interventions Iron supplementation group: approximately 2 mg/kg/day of iron (as formula containing
12 mg per quart (13 mg/L) of iron (n = 69)
No iron supplementation group: formula containing no added iron (n = 76)
Enrolled in the first week of life
Outcomes Primary outcome: incidence of iron deficiency (haemoglobin level below9.0 g/dL, hema-
tocrit below 0.32)
Secondary outcomes: haemoglobin concentration, red blood cell count, white blood cell
count, hematocrit, red cell indices. Weight and length
Timing: first week of life, as required during admission, and at each clinic visit after
discharge (up to 80 weeks postnatal)
Notes Management of anaemia: whenHb<9 g/dL andHcT<0.32, changed to iron-containing
formula. Infants in the control group removed from further analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not stated
Allocation concealment (selection bias) Low risk Blinding of randomisation: yes (sealed en-
velopes)
Blinding (performance bias and detection
bias)
All outcomes
Low risk Blinding of intervention: yes
Blinding of outcome measurement: yes
Incomplete outcome data (attrition bias)
All outcomes
High risk Complete follow-up: no (55.9% at 12
months)
Selective reporting (reporting bias) Unclear risk No known selectivity
Other bias Low risk No other risk of bias identified
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Griffin 1999
Methods Blinding of randomisation: yes (author communication)
Blinding of intervention: yes
Complete follow-up: yes (96.2%)
Blinding of outcome measurement: yes
Participants Gestation: 32 weeks or less
Birth weight: 1750 g or less
Feeding: formula feeding after commencement of intervention
Exclusions: systemically unwell, requiring supplemental oxygen, or on any medications
other than vitamin drops
Blood transfusion policy: permitted before enrolment (at discharge), but infants excluded
from study if required after enrolment
Interventions Iron supplementation group: approximately 1.5 mg/kg/day of iron (in formula contain-
ing 9 mg/L of iron) (n = 29)
No iron supplementation group: approximately 0.8 mg/kg/day of iron (in formula con-
taining 5 mg/L of iron) (n = 34)
Iron supplementation commenced at discharge from hospital
Short duration group: 9 mg/L (approximately 1.5 mg/kg/day) of iron (as high iron
formula) from discharge, then changed to the lower iron formula at term (n = 15)
Prior to discharge the infants received the high-iron formula or a combination of breast
milk and formula feeds
Outcomes Primary outcomes: haemoglobin concentration and plasma ferritin
Timing: every 2 weeks from discharge to term, then monthly to 6 months corrected age
(approximately 8 months postnatal age)
Notes Infants were randomised using sealed envelopes 48 hours before discharge. Three infants
were excluded from analysis because they received blood transfusions after discharge.
The outcome statistics are presented in graphical form, with statistical significance data
derived by ANOVA
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated (author communica-
tion)
Allocation concealment (selection bias) Low risk Blinding of randomisation: yes (author
communication)
Blinding (performance bias and detection
bias)
All outcomes
Low risk Blinding of intervention: yes
Blinding of outcome measurement: yes
Incomplete outcome data (attrition bias)
All outcomes
Low risk Complete follow-up: yes (96.2%)
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Griffin 1999 (Continued)
Selective reporting (reporting bias) Unclear risk No known selectivity
Other bias Low risk No other risk of bias identified
Groh-Wargo 1990
Methods Blinding of randomisation: not known
Blinding of intervention: yes (double-blind)
Complete follow-up: not known
Blinding of outcome assessment: not known
Participants Gestation: no limit stated
Birth weight: less than 1500 g birth weight
Feeding: low-iron formula
Exclusions: none stated
Blood transfusion policy: permitted
Interventions High iron group (HiFe) (Group 2): iron supplementation (as Fer-in-Sol) of 4 mg/kg/
day (n = 18)
Low iron group (MidFe) (Group 1): iron supplementation (as Fer-in-Sol) of 2 mg/kg/
day (n = 18)
Iron supplementation was commenced at 2 weeks postnatal age
Outcomes Primary outcomes: weight, haemoglobin, MCV, FEP, % saturation and ferritin
Timing: 0.5 months, 2 months, and 4 months
Notes There is no description of the number of eligible patients who were not included in the
trial
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not stated
Allocation concealment (selection bias) Unclear risk Blinding of randomisation: not known
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Blinding of intervention: yes (double-
blind)
Blinding of outcome assessment: not
known
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Complete follow-up: not known
Selective reporting (reporting bias) Unclear risk No known selectivity
32Enteral iron supplementation in preterm and low birth weight infants (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Groh-Wargo 1990 (Continued)
Other bias Unclear risk Insufficient information to inform assess-
ment of risk of other bias
Gross 1985
Methods Blinding of randomisation: not known
Blinding of intervention: not known
Complete follow-up: yes (100%)
Blinding of outcome assessment: not known
Participants Gestation: 27 to 33 weeks
Birth weight: < 1500 g (AGA)
Feeding: breast milk or formula
Exclusions: any major disease or haemolytic disease, hematocrit level < 0.40, unable to
begin enteral feeds in first week of life
Transfusions: nil received
Interventions Iron supplementation group: 2 mg/kg/day of iron as ferrous sulfate, from 2 weeks of age
(fed preterm human milk, mature human milk or formula)
No iron supplementation group: no ferrous sulfate (fed preterm human milk, mature
human milk or formula)
Outcomes Primary outcome: serum vitamin E concentration
Secondary outcomes: vitamin E/lipid ratio, hydrogen peroxide haemolysis, hematocrit,
reticulocyte count
Timing: day 1 and after 6 weeks of feeding (0 to 7 weeks postnatal) (vitamin Emeasures)
and 2 weeks and 4 weeks of feeding (2 to 5 weeks postnatal) (other measures)
Notes The infants were assigned to 1 of 6 groups by means of a random number table. Follow-
up was complete
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number table
Allocation concealment (selection bias) Unclear risk Blinding of randomisation: not known
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Blinding of intervention: not known
Blinding of outcome assessment: not
known
Incomplete outcome data (attrition bias)
All outcomes
Low risk Complete follow-up: yes (100%)
Selective reporting (reporting bias) Unclear risk No known selectivity
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Gross 1985 (Continued)
Other bias Low risk No other risk of bias identified
Hall 1993
Methods Blinding of randomisation: not known
Blinding of intervention: yes (double-blind)
Complete follow-up: no (37.3%)
Blinding of outcome measurement: yes
Participants Gestation: less than 35 weeks
Birth weight: less than 1800 g (AGA)
Feeding: formula or breast fed
Exclusions: chronic lung disease, NEC, neurological disease interfering with nutrition,
other conditions affecting nutrient intake
Blood transfusions: permitted
Interventions Iron supplementation group: approximately 2.4 mg/kg/day of iron (in formula contain-
ing 15 mg/L of iron) (n = 36)
No iron supplementation group: approximately 0.5 mg/kg/day of iron (in formula con-
taining 3 mg/L of iron) (n = 43)
The above formulas were used from study entry to discharge
At the time of hospital discharge, all formula-fed infants were changed to a cow-milk
based formula containing 12 mg/L of iron
Futher group not included in systematic review: ’Comparison group’ receiving breast
milk fortified with iron to provide 1.7 mg/L of iron (n = 71)
Outcomes Primary outcomes: plasma iron, ferritin, transferrin, transferrin saturation
Secondary outcomes: haemoglobin, hematocrit, red blood cell count, MCV, MCH,
MCHC and reticulocyte count. Weight, length, head circumference, arm circumference
and triceps skinfold thickness
Timing: haematological outcomes: study entry (up to 21 days postnatal), hospital dis-
charge (approximately 5 to 6 weeks postnatal), and 8 weeks after discharge (approxi-
mately 13 to 14 weeks postnatal). Anthropomorphic outcomes: study entry, hospital
discharge and 2, 4, 8 and 12 weeks postdischarge
Notes Themethod of randomisation was not described. Infants were enrolled within 21 days of
birth. 56 infants completed the study (37.3%) - 20/36 in the high iron (HiFe) formula
group, 23/43 in the low iron (MidFe) formula group, and 13/71 in the breast milk group
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not reported
Allocation concealment (selection bias) Unclear risk Blinding of randomisation: not known
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Hall 1993 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk Blinding of intervention: yes (double-
blind)
Blinding of outcome measurement: yes
Incomplete outcome data (attrition bias)
All outcomes
High risk Follow up to completion: 37.3%
Selective reporting (reporting bias) Unclear risk No known selectivity
Other bias Low risk No other risk of bias identified
Halliday 1983
Methods Blinding of randomisation: yes (author communication)
Blinding of intervention: yes (placebo used)
Complete follow-up: not known (100% follow-up implied)
Blinding of outcome measurement: yes (author communication)
Participants Gestational age 28 to 36 weeks
Birth weight: no limit stated
Feeding: mostly fed evaporated milk supplemented with a multivitamin preparation
Exclusions: significant respiratory problems, SGA
Blood transfusion: nil received
Interventions Iron supplementation group (also early iron group) (Group A): approximately 6 mg/kg/
day (12 mg) of elemental iron (as ferrous sulphate with ascorbic acid) until one year of
age (n = 16)
No iron supplementation group (Group B): ascorbic acid solution without iron until 1
year of age (n = 17)
Late iron group (GroupC): placebountil 8weeks, then6mg/kg/day (12mg) of elemental
iron daily until 1 year of age (n = 16)
Iron supplementation was commenced on the 7th day of life and increased from 2 mg
to 12 mg daily by the 6th week
Outcomes Primary outcomes: iron intake, haemoglobin concentration, serum iron, serum trans-
ferrin and serum ferritin
Timing: day 3 postnatally, then 3 weekly until 12 weeks and then at 18, 24, 36 and 54
weeks postnatal
Notes Themethodof randomisation and themeans of allocation concealment are not described.
However, the author indicated in correspondence that the randomisation was generated
by a statistician and allocationwas by sealed envelopes.No loss to follow-upwas recorded,
although the number of babies analysed at each time interval is not specified
Risk of bias
Bias Authors’ judgement Support for judgement
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Halliday 1983 (Continued)
Random sequence generation (selection
bias)
Low risk Author communication
Allocation concealment (selection bias) Low risk Blinding of randomisation: yes (author
communication)
Blinding (performance bias and detection
bias)
All outcomes
Low risk Blinding of intervention: yes (placebo
used)
Blinding of outcome measurement: yes
(author communication)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Complete follow-up: not known (100%
follow-up implied)
Selective reporting (reporting bias) Unclear risk No known selectivity
Other bias Low risk No other risk of bias identified
Hanninen 1961
Methods Blinding of randomisation: no (quasi-randomised) to one of three groups
Blinding of intervention: not known
Complete follow-up: not known
Blinding of outcome measurement: not known
Participants Gestation: preterm
Birth weight: between 1060 g to 2400 g
Feeding: not stated
Management of anaemia: excluded from analysis
Interventions Iron supplementation group (Group 1): approximately 27 mg/kg/day of iron (as ferri-
cholincitrate equivalent to 24 mg of iron twice daily) from the fourth week of life
No iron supplementation group (Group 3): no supplemental iron
Further group (Group 2) not included in the systematic review: approximately 64 mg/
kg/day of iron (as ferrogluconate equivalent to 29 mg of iron 4 times a day) from the
fourth week of life
Total n = 95: breakdown of infant numbers into study groups is not given
Outcomes Primary outcome: haemoglobin, MCH
Timing: day 1 postnatal, 3 weeks of age, 3 months and six months postnatal
Notes Infants were assigned on the basis of their order of admission. It is not clear whether
the feeding method was the same between the two groups. It is stated that some of the
babies in the control group were excluded because of anaemia. However, the rate of study
completion was not stated
Risk of bias
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Hanninen 1961 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quasi-randomised
Allocation concealment (selection bias) High risk Blinding of randomisation: no (quasi-ran-
domised) to one of three groups
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Blinding of intervention: not known
Blinding of outcome measurement: not
known
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Complete follow-up: not known
Selective reporting (reporting bias) Unclear risk No known selectivity
Other bias Low risk No other known risk of bias
Jansson 1979
Methods Blinding of randomisation: not known
Blinding of intervention: not known
Complete follow-up: yes (90.3%)
Blinding of outcome measurement: not known
Participants Gestation: 35 weeks or less
Birth weight: 2000 g or less
Feeding: human milk until at least 2 weeks of age or a weight of 2100 g. From this point,
they either continued to receive their mother’s milk, or a formula containing 10 mg/L
of ferrous sulphate
Exclusions: initial haemoglobin level below150g/Lor above 260 g/L; signs or haemolysis
Blood transfusions: excluded
Interventions Early iron group (Group A) : 2 to 3 mg/kg/day of iron (as ferrous succinate) from 3
weeks of age (n = 15)
Late iron group (GroupB): 2 to 3mg/kg/day of iron (as ferrous succinate) from2months
of age (n = 13)
Both groups received the same vitamin supplement
Outcomes Primary outcome: serum ferritin
Secondary outcomes: haemoglobin concentration, reticulocyte count, platelet count
Timing: 24hours, 8 to 10 weeks and 6 months of age
Notes 3 infants were subsequently excluded for not following the feeding regimen, leaving 28
infants for analysis (90.3%). It is recorded that 2 infants were partially breast fed while
receiving iron-fortified formula; which group these belonged to is not documented, nor
the possible effect of this on the results taken into account. Both groups received iron-
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Jansson 1979 (Continued)
fortified formula in addition to the intervention (early or late enteral iron supplementa-
tion)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not reported
Allocation concealment (selection bias) Unclear risk Blinding of randomisation: not known
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Blinding of intervention: not known
Blinding of outcome measurement: not
known
Incomplete outcome data (attrition bias)
All outcomes
Low risk Complete follow-up: yes (90.3%)
Selective reporting (reporting bias) Unclear risk No known selectivity
Other bias Low risk No other risk of bias identified
Lundstrom 1977
Methods Blinding of randomisation: no (quasi-randomised)
Blinding of intervention: not known
Complete follow-up: yes (117/125, 93.6%), but 53 excluded from analysis
Blinding of outcome measurement: not known
Participants Birth weight: 1050 g to 2000 g
Feeding: all received breast milk in hospital. The continuation of breastfeeding was
encouraged after discharge, but some were weaned to formula. Exclusions: if clinical
course had been complicated before 2 weeks of age. Any infant requiring an exchange
transfusion was excluded
Transfusions: those requiring transfusion after enrolment were subsequently excluded
Interventions Iron supplementation group: ferrous sulfate 2 mg/kg/day (as ferrous sulfate) from 2
weeks of age (n = 60). Some of these were weaned to a formula containing 11 mg/L
of iron (providing approximately 1.8 mg/kg/day of iron), and thus had their oral iron
supplement ceased
No iron supplementation group: no iron supplementation (n = 57)
Outcomes Primary outcomes: haemoglobin concentration, serum iron, total iron binding capacity,
serum ferritin, reticulocyte count, platelet count
Timing: 2 weeks, 1 month postnatal, then monthly until 6 months postnatal
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Lundstrom 1977 (Continued)
Notes Allocation to groups was based on birth date. 7 infants were excluded for receiving
blood transfusions, and one for being diagnosed with hereditary spherocytosis. 44 of the
unsupplemented group were excluded from analysis as they developed anaemia requiring
iron therapy. A further 9 were inadvertently started too early on iron therapy, and also
excluded
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quasi-randomised
Allocation concealment (selection bias) High risk Blinding of randomisation: no (quasi-ran-
domised)
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Blinding of intervention: not known
Blinding of outcome measurement: not
known
Incomplete outcome data (attrition bias)
All outcomes
Low risk Follow-up to completion: 93.6%
Selective reporting (reporting bias) Unclear risk No known selectivity
Other bias Low risk No other risk of bias identified
Melhorn 1971
Methods Blinding of randomisation: not known
Blinding of intervention: not known
Complete follow-up: yes (79%)
Blinding of outcome measurement: not known
Participants Gestation: before 40 weeks
Birth weight: below 2400 g
Feeding: formula
Exclusions: pre-existing haematological abnormalities, infections or surgery, SGA or
LGA
Interventions Iron supplementation group: approximately 8.7 mg/kg/day of iron as 10 mg, 15 mg or
20 mg of oral iron daily, depending on birth weight (< 1500 g, 1501 g to 2000 g and
2001 g to 2400 g respectively), with (Group 4, n = 50) or without (Group 3, n = 44)
the addition of vitamin E, 25 IU/day orally
No iron supplementation group: no supplement (Group 1, n = 45) or vitamin E, 25 IU/
day orally (Group 2, n = 47)
Vitamin E was given from the 8th to the 42nd day of life, and iron from the 15th to the
42nd day. All infants were fed a low iron formula (1.5 mg/L, or approximately 0.2 mg/
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Melhorn 1971 (Continued)
kg/day of iron) while in hospital, but on discharge the babies in the iron supplementation
group received a high iron formula (8.4 mg/L, or approximately 1.3 mg/kg/day of iron)
Outcomes Primary outcomes: haemoglobin, hematocrit, reticulocyte count, platelet count, red cell
fragility, serum tocopherol, serum iron
Timing: day 1 postnatal, then weekly until 4 weeks, then 2 to 4 weekly until 16 weeks
postnatal
Notes Infants in the groups receiving iron supplementation received an iron-fortified formula
between hospital discharge and 4 months of age (8 mg/quart or 8.4 mg/L of iron), and
the others a low iron formula (1.4 mg/quart or 1.5 mg/L). As planned, infants who
developed a haemoglobin concentration below 75 g/L were removed from the study. Of
the 234 infants enrolled, 186 were studied. 38 infants were removed from the study, 10
because of haemoglobin levels below 75 g/L
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not stated
Allocation concealment (selection bias) Unclear risk Blinding of randomisation: not known
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Blinding of intervention: not known
Blinding of outcome measurement: not
known
Incomplete outcome data (attrition bias)
All outcomes
Low risk Complete follow-up: yes (79%)
Selective reporting (reporting bias) Unclear risk No known selectivity
Other bias Low risk No other risk of bias identified
Melnick 1988
Methods Blinding of randomisation: no (author communication)
Blinding of intervention: no (author communication)
Complete follow-up: not known (implied to be complete)
Blinding of outcome measurement: no (author communication)
Participants 38 LBW (AGA) infants
Interventions Iron supplementation group: approximately 2.4 mg/kg/day of iron (in formula contain-
ing 15 mg/L of iron)
No iron supplementation group: approximately 0.8 mg/kg/day of iron (in formula con-
taining 3.5 mg/L of iron)
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Melnick 1988 (Continued)
Total n = 19
Outcomes Primary outcomes: haemoglobin, serum ferritin, transferrin concentration
Timing: study entry, day 15 and day 29 (postnatal age uncertain but estimated to be
approximately 2 weeks, 4 weeks and 6 weeks postnatal)
Notes The number of infants in each study group is not recorded, nor is the adequacy of follow-
up. No loss to follow-up was recorded
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not stated
Allocation concealment (selection bias) High risk Blinding of randomisation: no (author
communication)
Blinding (performance bias and detection
bias)
All outcomes
High risk Blinding of intervention: no (author com-
munication)
Blinding of outcomemeasurement: no (au-
thor communication)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Complete follow-up: not known (implied
to be complete)
Selective reporting (reporting bias) Unclear risk No known selectivity
Other bias Low risk No other risk of bias identified
Quilligan 1954
Methods Blinding of randomisation: no (quasi-randomised)
Blinding of intervention: not known
Complete follow-up: no (approximately 50%)
Blinding of outcome measurement: not known
Participants 38 premature infants. The mean weight and gestation of the cohort was not reported
Feeding method: not known
Blood transfusion policy: not stated
Interventions Iron supplementation group (Group 3): approximately 10 mg/kg/day of iron (as ferrous
sulfate, 22.5 mg/day), and 40 mg of cobalt chloride daily
No iron supplementation group (Group 1): no supplement (n = 12)
Further group, not included in systematic review (Group 2): 75 mg of ferrous sulfate
mixture daily (n = 10) (no data on this group because of loss to follow-up)
41Enteral iron supplementation in preterm and low birth weight infants (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Quilligan 1954 (Continued)
Outcomes Primary outcomes: haemoglobin, hematocrit, red blood cell count, reticulocyte count
Secondary outcome: weight
Timing: weekly while the infants were inpatients, approximately every 10 days after
discharge, up to 60 days postnatal
Notes Divided on a quasi-randomised fashion (based on ’serial admissions’). It is not clear
whether the groups were treated equally in all other respects; for example, the method
of feeding is not documented. The authors reported a poor follow-up rate, but did not
publish exact numbers. Attendence at the follow-up visits was variable, with as few as 5
of 12 infants in the control group presenting in day 41 to 50 and 8 of 16 in the treatment
group being tested on day 51 to 60
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quasi-randomised
Allocation concealment (selection bias) High risk Blinding of randomisation: no (quasi-ran-
domised)
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Blinding of intervention: not known
Blinding of outcome measurement: not
known
Incomplete outcome data (attrition bias)
All outcomes
High risk Complete follow-up: no (approximately
50%)
Selective reporting (reporting bias) Unclear risk No known selectivity
Other bias Unclear risk Insufficient information
Reedy 1952
Methods Blinding of randomisation: no (quasi-randomised)
Blinding of intervention: no (no placebo)
Complete follow-up: no (20.7%)
Blinding of outcome assessment: not known
Participants Gestation: premature
Birth weight: 2268 g or below
Feeding: breast milk initially, with most changed later to a formula
Exclusions: poor clinic attendance
Blood transfusion: excluded from study
42Enteral iron supplementation in preterm and low birth weight infants (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Reedy 1952 (Continued)
Interventions Iron supplementation group (Group 1): approximately 1.3 mg/kg/day of iron until
discharge, then approximately 5.4 mg/kg/day of iron, as iron mixture. The iron mixture
consisted of a mixture of liver concentrate, copper sulfate, iron and ammonium citrate
(elemental iron 66 mg per ounce, or approximately 2.3 mg/mL), at a dose of 15 drops
(approximately 1.4 mg iron) per day as inpatients, and 1 teaspoon (approximately 11.5
mg) per day from discharge (at standard discharge weight of 2126 g) (n = 30)
Control group: no supplement or placebo (n = 32)
Short duration group: iron mixture for the first three months only (n = 17)
Outcomes Primary outcomes: red cell count, haemoglobin, reticulocyte count, leukocyte count,
eosinophil count
Secondary outcome: weight
Timing: 24 to 48 hours postnatal, every 7 days while inpatients, then monthly as out-
patients until 12 months postnatal
Notes Infants were assigned on the basis of their order of admission to the nursery (i.e. quasi-
randomised), with alternate infants receiving iron supplementation from the 7th day
of life. 382 babies were commenced on the study; 24 discontinued because of need for
blood transfusion; 10 were excluded because of poor clinic attendance; and 269 were
lost to follow-up or died. Thus, 79 infants were included in the analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quasi-randomised
Allocation concealment (selection bias) High risk Blinding of randomisation: no (quasi-ran-
domised)
Blinding (performance bias and detection
bias)
All outcomes
High risk Blinding of intervention: no (no placebo)
Blinding of outcome assessment: not
known
Incomplete outcome data (attrition bias)
All outcomes
High risk Complete follow-up: no (20.7%)
Selective reporting (reporting bias) Unclear risk No known selectivity
Other bias Low risk No other risk of bias identified
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Rudolph 1981
Methods Blinding of randomisation: yes (author communication)
Blinding of intervention: no
Complete follow-up: no (60% at 6 weeks)
Blinding of outcome measurement: yes
Participants Gestation: 32 weeks or less
Birth weight: 1001 to 1600 g
Feeding: formula
Exclusions: haemolytic disease, clinical illness, or a hematocrit level > 0.38 on day 5 to
6
Transfusions: policy not stated
Interventions Iron supplementation group: approximately 1.9 mg/kg/day of iron (in formula contain-
ing 12 mg/L of iron) (formula A1) (n = 10)
No iron supplementation group: cow’s milk-based formula containing only a trace of
iron (formula A) (n = 10)
Further group not analysed in systematic review: soy-based formula containing 12 mg/
L of iron (n = 10)
Outcomes Primary outcomes: haemoglobin, hematocrit, reticulocytes, hydrogen peroxide haemol-
ysis, serum cholesterol, serum vitamin E
Secondary outcomes: red cell and plasma selenium
Timing: weekly until 6 weeks postnatal
Notes Assignment was at 5 to 6days of age. There was no cross-over in groups for analysis. 30
infants were entered into the study. Of these 26 were followed up until 6 weeks of age,
or hospital discharge at approximately 5 weeks of age. 18/30 (60%) were analysed at 6
weeks
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not stated
Allocation concealment (selection bias) Low risk Blinding of randomisation: yes (author
communication)
Blinding (performance bias and detection
bias)
All outcomes
High risk Blinding of intervention: no
Blinding of outcome measurement: yes
Patient care staff were not blinded; labora-
tory personnel were blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk Follow-up to completion: 60%
Selective reporting (reporting bias) Unclear risk No known selectivity
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Rudolph 1981 (Continued)
Other bias Low risk No other risk of bias identified
Sankar 2009
Methods Blinding of randomisation: yes
Blinding of intervention: no
Complete follow-up: yes (91%)
Blinding of outcome measurement: yes
Participants Gestation: mean 32 weeks, all preterm
Birthweight: < 1500 g (mean approximately 1200 g)
Feeding: > 90% exclusively or predominantly breast fed at enrolment
Exclusions: major anomalies; rhesus haemolytic disease
Transfusions: permitted (restrictive policy)
Interventions Iron supplementation group (enteral colloidal iron preparation): 3 mg/kg/day (birth
weight 1000 g to 1500 g) or 4 mg/kg/day (birth weight < 1000 g); preparation also
contained folic acid (200 mcg/mL) and vitamin B12 (5 mcg/mL). Formula fed babies
received iron-fortified formula (13.6 mg/L), with equivalent iron amount subtracted
from daily supplement
Control group: no iron supplement. No placebo control. Formula fed babies received
iron-fortified formula (13.6 mg/L)
Outcomes Primary outcome: serum ferritin at 60 days
Secondary outcomes (at 60 days): haemoglobin concentration; hematocrit; weight; re-
quirement for blood transfusion; re-hospitalisation; composite of morbidities (NEC,
PVL, ROP, CNLD); sepsis/pneumonia
Notes All infants received recommended intake of vitamins including folic acid and B12
through breast milk fortification or infant formula
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generation
Allocation concealment (selection bias) Low risk Blinding of randomisation: yes
Blinding (performance bias and detection
bias)
All outcomes
High risk Blinding of intervention: no
Blinding of outcome measurement: yes
Incomplete outcome data (attrition bias)
All outcomes
Low risk Follow-up to completion: 91%
45Enteral iron supplementation in preterm and low birth weight infants (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Sankar 2009 (Continued)
Selective reporting (reporting bias) Unclear risk No known selectivity
Other bias Low risk No other risk of bias identified
Steinmacher 2007
Methods Blinding of randomisation: no (author communication)
Blinding of intervention: yes; but allocation became obvious due to stool colour
Complete follow-up: yes (85%)
Blinding of outcome measurement: yes
Participants Gestation: no limit
Birth weight: less than 1301 g
Feeding: either breast fed, or received an iron-fortified formula (12 mg/L, or approxi-
mately 1.9 mg/kg/day of iron)
Exclusion criteria: major anomalies, haemolytic disease and twin-to-twin transfusion
Blood transfusion policy: permitted, before and after entry; restrictive transfusion policy
Interventions Iron supplementation group: 2 mg/kg/day of iron as ferrous sulfate, commenced as soon
as enteral feedings were tolerated (n = 105)
No iron supplementation group: 2 mg/kg/day of iron as ferrous sulfate, commenced at
61 days of life (n = 99)
Management of anaemia: when the hematocrit level fell below 0.30, the dose of iron was
increased to 4 mg/kg/day. The policy for the administration of blood transfusions was
clearly outlined
Outcomes Primary outcome: serum ferritin and incidence of iron deficiency
Secondary outcomes: transferrin, transferrin saturation, serum iron, reticulocytes, hema-
tocrit; number of transfusions required and blood volume transfused
Additional outcomes at 5 years of age: clinical neurological examination; mobility assess-
ment (Gross Motor Functioning Classification Scale (GMFCS)); motor co-ordination
(Lincoln-Oseretzky Scale (short form) 18); cognitive function (Kaufmann Assessment
Battery for Children, including MPC); visual assessment; behaviour (Child Behaviour
Check List)
Notes This study was a continuation of Franz 2000, using the original randomised cohort
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generation
Allocation concealment (selection bias) High risk Blinding of randomisation: no (author
communication)
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Steinmacher 2007 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Blinding of intervention: yes; but alloca-
tion became obvious due to stool colour
Blinding of outcome measurement: yes
Incomplete outcome data (attrition bias)
All outcomes
Low risk Complete follow-up: yes (85%)
Selective reporting (reporting bias) Unclear risk No known selectivity
Other bias Low risk No other risk of bias identified
ANOVA: analysis of variance
AGA: appropriate for gestational age
BUN: blood urea nitrogen
EPO: erythropoietin
FEP: free erythrocyte porphyrin
Hb: haemoglobin
HcT: hematocrit
HMF: human milk fortifiers
IU: international units
IVH: intraventricular haemorrhage
MCH: mean cell haemoglobin
MCHC: mean cell haemoglobin concentration (or mean erythrocyte haemoglobin concentration)
MCV: mean corpuscular volume
NEC: necrotising enterocolitis
RCC: red cell count
SGA: small for gestational age
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Arnon 2007 All study subjects were included in Arnon 2009. All outcomes are included in Arnon 2009 (published and
unpublished data)
Brozovic 1974 Not a controlled trial of iron
Carnielli 1998 Oral versus IV iron
Creutz 1958 Not an RCT
Del Mundo 1964 Not preterm or low birth weight infants
Dewey 2004 Intervention is not iron supplementation, and 4 to 6 month old infants
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(Continued)
Friel 1995 IV iron administration
Friel 2003 Study population is term infants of normal birth weight
Fydryk 1962 Not a controlled trial
Garry 1981 Study population is term infants of normal birth weight
Graeber 1977 IV iron only
Greer 1988 Not a trial of iron therapy
Gross 1974 Method of allocation not stated
Heese 1990 Compares IM and oral iron
James 1960 IV iron administered
Jobert 1975 Not an RCT
Kivivuori 1999 Oral versus IM iron
Lindberg 1973 Not an RCT
Meyer 1996 Oral versus IV iron
Miller 2006 Not an RCT
Naude 2000 Two groups received same iron dose, but different oral formulations
Nazir 2002 Subjects were on erythropoietin treatment
Nelson 1988 Study population is term infants
Niccum 1953 Not an RCT
Olivares 1992 Not an RCT
Oski 1972 Letter to the editor - not an RCT
Owen 1981 Study population is term infants
Picciano 1980 Study population is term infants
Rothe-Meyer 1953 Not an RCT
Saarinen 1978 Study population is term infants
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(Continued)
Siep 1956 Not an RCT
Singhal 2000 Study population term babies with normal birth weight
Sitarz 1960 IV iron administered
Tevetoglu 1958 Not an RCT
Tuttle 1952 Not an RCT
Victorin 1984 Not an RCT
IM: intramuscular
IV: intravenous
RCT: randomised controlled trial
Characteristics of studies awaiting assessment [ordered by study ID]
Hurgoiu 1986
Methods Awaiting translation
Participants
Interventions
Outcomes
Notes
Neimann 1957
Methods Awaiting translation
Participants
Interventions
Outcomes
Notes
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D A T A A N D A N A L Y S E S
Comparison 1. Enteral iron supplementation versus no iron supplementation
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Weight at 12 months or less 4 Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.1 Full or partial breast
feeding, or not stated
4 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Length at 12 months or less 3 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.1 Full or partial breast
feeding, or not stated
3 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Head circumference at 12
months or less
3 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3.1 Full or partial breast
feeding, or not stated
3 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Haemoglobin concentration at 6
to 8 weeks
9 526 Mean Difference (IV, Fixed, 95% CI) 1.43 [-0.20, 3.07]
5 Haemoglobin concentration at 3
to 4 months
5 269 Mean Difference (IV, Fixed, 95% CI) 2.46 [-0.04, 4.95]
6 Haemoglobin concentration at 6
to 9 months
3 458 Mean Difference (IV, Fixed, 95% CI) 5.91 [4.25, 7.58]
6.1 Fully formula fed 2 132 Mean Difference (IV, Fixed, 95% CI) 6.56 [3.07, 10.05]
6.2 Full or partial breast
feeding, or not stated
1 165 Mean Difference (IV, Fixed, 95% CI) 8.0 [5.20, 10.80]
6.3 Full or partial
breastfeeding (1 mg/kg/day
iron)
1 161 Mean Difference (IV, Fixed, 95% CI) 3.80 [1.23, 6.37]
7 Haemoglobin concentration at
12 months
1 81 Mean Difference (IV, Fixed, 95% CI) 16.0 [10.66, 21.34]
8 Serum ferritin at 6 to 8 weeks 3 124 Mean Difference (IV, Fixed, 95% CI) 6.70 [0.13, 13.27]
9 Serum ferritin at 3 to 4 months 3 104 Mean Difference (IV, Fixed, 95% CI) 11.13 [0.74, 21.52]
10 Serum ferritin at 6 to 9 months 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
10.1 2 mg/kg/day 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.2 1 mg/kg/day 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
11 MCV at 6 to 9 months 1 326 Mean Difference (IV, Fixed, 95% CI) 2.10 [1.24, 2.96]
11.1 2 mg/kg/day iron 1 165 Mean Difference (IV, Fixed, 95% CI) 2.5 [1.28, 3.72]
11.2 1 mg/kg/day iron 1 161 Mean Difference (IV, Fixed, 95% CI) 1.70 [0.49, 2.91]
12 Transferrin saturation at 6 to 8
weeks
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
13 Transferrin saturation at 3 to 4
months
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
14 Transferrin saturation at 6 to 9
months
1 326 Mean Difference (IV, Fixed, 95% CI) 7.14 [5.19, 9.08]
14.1 2 mg/kg/day iron 1 165 Mean Difference (IV, Fixed, 95% CI) 9.10 [5.97, 12.23]
14.2 1 mg/kg/day iron 1 161 Mean Difference (IV, Fixed, 95% CI) 5.90 [3.42, 8.38]
15 Subgroup analyses - Hb at 6 to
8 weeks
9 Mean Difference (IV, Fixed, 95% CI) Subtotals only
50Enteral iron supplementation in preterm and low birth weight infants (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
15.1 Fully formula fed 5 389 Mean Difference (IV, Fixed, 95% CI) 0.71 [-1.14, 2.55]
15.2 Full or partial breast
feeding, or not stated
4 137 Mean Difference (IV, Fixed, 95% CI) 4.14 [0.59, 7.70]
15.3 Early commencement 8 463 Mean Difference (IV, Fixed, 95% CI) 1.55 [-0.12, 3.23]
15.4 Late commencement 1 63 Mean Difference (IV, Fixed, 95% CI) -1.10 [-8.82, 6.62]
15.5 Low dose 3 209 Mean Difference (IV, Fixed, 95% CI) 3.92 [1.53, 6.32]
15.6 High dose 6 317 Mean Difference (IV, Fixed, 95% CI) -0.76 [-3.01, 1.49]
15.7 Under 1500 g mean
birth weight
5 203 Mean Difference (IV, Fixed, 95% CI) -0.42 [-4.27, 3.43]
15.8 1500 g or over mean
birth weight
3 305 Mean Difference (IV, Fixed, 95% CI) 0.77 [-1.16, 2.69]
16 Enteral feed intolerance 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
17 Subgroup analyses - Hb at 3 to
4 months
5 Mean Difference (IV, Fixed, 95% CI) Subtotals only
17.1 Fully formula fed 3 208 Mean Difference (IV, Fixed, 95% CI) 2.39 [-0.42, 5.21]
17.2 Full or partial breast
feeding
2 61 Mean Difference (IV, Fixed, 95% CI) 2.69 [-2.70, 8.08]
17.3 Early commencement 3 180 Mean Difference (IV, Fixed, 95% CI) 0.75 [-2.36, 3.85]
17.4 Late commencement 2 89 Mean Difference (IV, Fixed, 95% CI) 5.59 [1.39, 9.79]
17.5 Low dose 2 165 Mean Difference (IV, Fixed, 95% CI) 4.0 [0.85, 7.15]
17.6 High dose 3 104 Mean Difference (IV, Fixed, 95% CI) -0.15 [-4.24, 3.94]
17.7 Under 1500 g mean
birth weight
2 106 Mean Difference (IV, Fixed, 95% CI) 0.98 [-2.89, 4.84]
17.8 1500 g or over birth
weight
3 163 Mean Difference (IV, Fixed, 95% CI) 3.52 [0.25, 6.79]
Comparison 2. Early versus late iron supplementation
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Neurodevelopmental outcome
(MPC) at 5 years
1 164 Mean Difference (IV, Fixed, 95% CI) 3.0 [-2.06, 8.06]
2 Haemoglobin concentration at 6
to 8 weeks
2 144 Mean Difference (IV, Fixed, 95% CI) 15.49 [12.74, 18.24]
3 Haemoglobin concentration at 6
to 9 months
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
4 Ferritin level at 6 to 8 weeks 1 116 Mean Difference (IV, Fixed, 95% CI) 25.0 [16.94, 33.06]
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Comparison 3. High dose versus low dose iron supplementation
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Neurodevelopmental outcome
(Grifiths Developmental
Assessment score) at 12 months
or less
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2 Haemoglobin concentration at 6
to 8 weeks
2 77 Mean Difference (IV, Fixed, 95% CI) -1.41 [-8.24, 5.42]
2.1 Full formula feeding 1 41 Mean Difference (IV, Fixed, 95% CI) -5.0 [-17.86, 7.86]
2.2 Full or partial breast
feeding, or not stated
1 36 Mean Difference (IV, Fixed, 95% CI) 0.0 [-8.06, 8.06]
3 Haemoglobin concentration at 3
to 4 months
3 117 Mean Difference (IV, Fixed, 95% CI) 4.49 [0.84, 8.13]
3.1 Full formula feeding 2 81 Mean Difference (IV, Fixed, 95% CI) 4.34 [0.21, 8.47]
3.2 Full or partial breast
feeding, or not stated
1 36 Mean Difference (IV, Fixed, 95% CI) 5.0 [-2.79, 12.79]
4 Haemoglobin concentration at 6
to 9 months
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
5 Haemoglobin concentration at
12 months
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
6 Mean corpuscular volume at 3
to 4 months
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
7 Serum ferritin at 6 to 8 weeks 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
8 Serum ferritin at 3 to 4 months 2 82 Mean Difference (IV, Fixed, 95% CI) 4.15 [-3.71, 12.02]
9 Serum ferritin at 6 to 9 months 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
10 Serum ferritin at 12 months 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
11 Transferrin saturation at 6 to 8
weeks
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
12 Transferrin saturation at 3 to 4
months
2 85 Mean Difference (IV, Fixed, 95% CI) 1.74 [-1.23, 4.71]
13 Transferrin saturation at 6 to 9
months
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
14 Transferrin saturation at 12
months
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
Comparison 4. Short duration versus long duration iron supplementation
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Haemoglobin at 6 to 8 weeks 1 44 Mean Difference (IV, Fixed, 95% CI) 3.70 [-3.79, 11.19]
2 Haemoglobin at 3 to 4 months 1 44 Mean Difference (IV, Fixed, 95% CI) 1.5 [-3.92, 6.92]
3 Haemoglobin at 6 to 9 months 1 44 Mean Difference (IV, Fixed, 95% CI) 5.70 [0.50, 10.90]
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Analysis 1.1. Comparison 1 Enteral iron supplementation versus no iron supplementation, Outcome 1
Weight at 12 months or less.
Review: Enteral iron supplementation in preterm and low birth weight infants
Comparison: 1 Enteral iron supplementation versus no iron supplementation
Outcome: 1 Weight at 12 months or less
Study or subgroup Treatment Control
Mean
Difference
Mean
Difference
N Mean(SD)[g] N Mean(SD)[g] IV,Fixed,95% CI IV,Fixed,95% CI
1 Full or partial breast feeding, or not stated
Aggarwal 2005 13 5669 (475) 13 5523 (370) 146.00 [ -181.30, 473.30 ]
Berglund 2010 82 6950 (630) 83 6830 (690) 120.00 [ -81.57, 321.57 ]
Ferlin 1998 10 2438 (200) 10 2686 (379) -248.00 [ -513.60, 17.60 ]
Sankar 2009 21 2272 (756) 23 2215 (736) 57.00 [ -384.61, 498.61 ]
-1000 -500 0 500 1000
Favours control Favours treatment
Analysis 1.2. Comparison 1 Enteral iron supplementation versus no iron supplementation, Outcome 2
Length at 12 months or less.
Review: Enteral iron supplementation in preterm and low birth weight infants
Comparison: 1 Enteral iron supplementation versus no iron supplementation
Outcome: 2 Length at 12 months or less
Study or subgroup Treatment Control
Mean
Difference
Mean
Difference
N Mean(SD)[cm] N Mean(SD)[cm] IV,Fixed,95% CI IV,Fixed,95% CI
1 Full or partial breast feeding, or not stated
Aggarwal 2005 13 58.9 (2) 13 57.3 (2) 1.60 [ 0.06, 3.14 ]
Berglund 2010 82 65.5 (2.1) 83 65 (2.1) 0.50 [ -0.14, 1.14 ]
Ferlin 1998 10 45.85 (1.65) 10 47.35 (2.55) -1.50 [ -3.38, 0.38 ]
-4 -2 0 2 4
Favours control Favours treatment
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Analysis 1.3. Comparison 1 Enteral iron supplementation versus no iron supplementation, Outcome 3
Head circumference at 12 months or less.
Review: Enteral iron supplementation in preterm and low birth weight infants
Comparison: 1 Enteral iron supplementation versus no iron supplementation
Outcome: 3 Head circumference at 12 months or less
Study or subgroup Treatment Control
Mean
Difference
Mean
Difference
N Mean(SD)[cm] N Mean(SD)[cm] IV,Fixed,95% CI IV,Fixed,95% CI
1 Full or partial breast feeding, or not stated
Aggarwal 2005 13 40.5 (1.8) 13 40.9 (2.1) -0.40 [ -1.90, 1.10 ]
Berglund 2010 82 42.6 (1.4) 83 42.4 (1.1) 0.20 [ -0.18, 0.58 ]
Ferlin 1998 10 33.95 (0.76) 10 34.15 (1.29) -0.20 [ -1.13, 0.73 ]
-4 -2 0 2 4
Favours treatment Favours control
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Analysis 1.4. Comparison 1 Enteral iron supplementation versus no iron supplementation, Outcome 4
Haemoglobin concentration at 6 to 8 weeks.
Review: Enteral iron supplementation in preterm and low birth weight infants
Comparison: 1 Enteral iron supplementation versus no iron supplementation
Outcome: 4 Haemoglobin concentration at 6 to 8 weeks
Study or subgroup Iron supplementation No iron supplement
Mean
Difference Weight
Mean
Difference
N Mean(SD)[g/L] N Mean(SD)[g/L] IV,Fixed,95% CI IV,Fixed,95% CI
Barclay 1991 16 96 (14.3) 19 96 (17.8) 2.4 % 0.0 [ -10.64, 10.64 ]
Ferlin 1998 20 82.5 (9.9) 20 85.2 (9.7) 7.3 % -2.70 [ -8.77, 3.37 ]
Gorten 1964 67 106 (8) 66 101 (7) 41.1 % 5.00 [ 2.45, 7.55 ]
Griffin 1999 29 98.5 (15.3) 34 99.6 (15.9) 4.5 % -1.10 [ -8.82, 6.62 ]
Hall 1993 20 97 (15) 23 90 (16) 3.1 % 7.00 [ -2.27, 16.27 ]
Melhorn 1971 70 92.9 (9.6) 67 98.1 (8.6) 28.8 % -5.20 [ -8.25, -2.15 ]
Quilligan 1954 13 120 (6.7) 5 110 (4.4) 9.5 % 10.00 [ 4.70, 15.30 ]
Rudolph 1981 7 72 (7.9) 6 86 (17.1) 1.2 % -14.00 [ -28.88, 0.88 ]
Sankar 2009 21 108 (18) 23 102 (21) 2.0 % 6.00 [ -5.53, 17.53 ]
Total (95% CI) 263 263 100.0 % 1.43 [ -0.20, 3.07 ]
Heterogeneity: Chi2 = 44.07, df = 8 (P<0.00001); I2 =82%
Test for overall effect: Z = 1.72 (P = 0.086)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
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Analysis 1.5. Comparison 1 Enteral iron supplementation versus no iron supplementation, Outcome 5
Haemoglobin concentration at 3 to 4 months.
Review: Enteral iron supplementation in preterm and low birth weight infants
Comparison: 1 Enteral iron supplementation versus no iron supplementation
Outcome: 5 Haemoglobin concentration at 3 to 4 months
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD)[g/L] N Mean(SD)[g/L] IV,Fixed,95% CI IV,Fixed,95% CI
Aggarwal 2005 13 117 (9) 13 107 (12) 9.4 % 10.00 [ 1.85, 18.15 ]
Barclay 1991 16 101 (12.2) 19 104 (8.9) 12.0 % -3.00 [ -10.19, 4.19 ]
Gorten 1964 55 100 (10) 47 96 (11) 36.9 % 4.00 [ -0.11, 8.11 ]
Griffin 1999 29 105 (9.6) 34 101 (10.2) 26.0 % 4.00 [ -0.90, 8.90 ]
Hall 1993 20 104 (10) 23 108 (11) 15.8 % -4.00 [ -10.28, 2.28 ]
Total (95% CI) 133 136 100.0 % 2.46 [ -0.04, 4.95 ]
Heterogeneity: Chi2 = 10.48, df = 4 (P = 0.03); I2 =62%
Test for overall effect: Z = 1.93 (P = 0.054)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours control Favours treatment
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Analysis 1.6. Comparison 1 Enteral iron supplementation versus no iron supplementation, Outcome 6
Haemoglobin concentration at 6 to 9 months.
Review: Enteral iron supplementation in preterm and low birth weight infants
Comparison: 1 Enteral iron supplementation versus no iron supplementation
Outcome: 6 Haemoglobin concentration at 6 to 9 months
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD)[g/L] N Mean(SD)[g/L] IV,Fixed,95% CI IV,Fixed,95% CI
1 Fully formula fed
Gorten 1964 37 113 (10) 32 98 (13) 9.0 % 15.00 [ 9.46, 20.54 ]
Griffin 1999 29 120 (8.6) 34 119 (9.6) 13.7 % 1.00 [ -3.50, 5.50 ]
Subtotal (95% CI) 66 66 22.7 % 6.56 [ 3.07, 10.05 ]
Heterogeneity: Chi2 = 14.80, df = 1 (P = 0.00012); I2 =93%
Test for overall effect: Z = 3.68 (P = 0.00023)
2 Full or partial breast feeding, or not stated
Berglund 2010 82 121.1 (10.1) 83 113.1 (8.1) 35.4 % 8.00 [ 5.20, 10.80 ]
Subtotal (95% CI) 82 83 35.4 % 8.00 [ 5.20, 10.80 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.61 (P < 0.00001)
3 Full or partial breastfeeding (1 mg/kg/day iron)
Berglund 2010 78 116.9 (8.5) 83 113.1 (8.1) 41.9 % 3.80 [ 1.23, 6.37 ]
Subtotal (95% CI) 78 83 41.9 % 3.80 [ 1.23, 6.37 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.90 (P = 0.0037)
Total (95% CI) 226 232 100.0 % 5.91 [ 4.25, 7.58 ]
Heterogeneity: Chi2 = 19.67, df = 3 (P = 0.00020); I2 =85%
Test for overall effect: Z = 6.97 (P < 0.00001)
Test for subgroup differences: Chi2 = 4.87, df = 2 (P = 0.09), I2 =59%
-100 -50 0 50 100
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Analysis 1.7. Comparison 1 Enteral iron supplementation versus no iron supplementation, Outcome 7
Haemoglobin concentration at 12 months.
Review: Enteral iron supplementation in preterm and low birth weight infants
Comparison: 1 Enteral iron supplementation versus no iron supplementation
Outcome: 7 Haemoglobin concentration at 12 months
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD)[g/L] N Mean(SD)[g/L] IV,Fixed,95% CI IV,Fixed,95% CI
Gorten 1964 49 116 (8) 32 100 (14) 100.0 % 16.00 [ 10.66, 21.34 ]
Total (95% CI) 49 32 100.0 % 16.00 [ 10.66, 21.34 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.87 (P < 0.00001)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours control Favours treatment
Analysis 1.8. Comparison 1 Enteral iron supplementation versus no iron supplementation, Outcome 8
Serum ferritin at 6 to 8 weeks.
Review: Enteral iron supplementation in preterm and low birth weight infants
Comparison: 1 Enteral iron supplementation versus no iron supplementation
Outcome: 8 Serum ferritin at 6 to 8 weeks
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mcg/L] N Mean(SD)[mcg/L] IV,Fixed,95% CI IV,Fixed,95% CI
Barclay 1991 16 75 (89.8) 19 71 (80.1) 1.3 % 4.00 [ -52.86, 60.86 ]
Hall 1993 20 88 (59) 23 54 (45) 4.3 % 34.00 [ 2.27, 65.73 ]
Sankar 2009 22 50.8 (11.5) 24 45.3 (11.9) 94.4 % 5.50 [ -1.26, 12.26 ]
Total (95% CI) 58 66 100.0 % 6.70 [ 0.13, 13.27 ]
Heterogeneity: Chi2 = 2.97, df = 2 (P = 0.23); I2 =33%
Test for overall effect: Z = 2.00 (P = 0.046)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours control Favours treatment
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Analysis 1.9. Comparison 1 Enteral iron supplementation versus no iron supplementation, Outcome 9
Serum ferritin at 3 to 4 months.
Review: Enteral iron supplementation in preterm and low birth weight infants
Comparison: 1 Enteral iron supplementation versus no iron supplementation
Outcome: 9 Serum ferritin at 3 to 4 months
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mcg/L] N Mean(SD)[mcg/L] IV,Fixed,95% CI IV,Fixed,95% CI
Aggarwal 2005 (1) 13 105.38 (77.07) 13 129.23 (133.84) 1.5 % -23.85 [ -107.81, 60.11 ]
Barclay 1991 16 41 (34.69) 19 40 (40) 17.6 % 1.00 [ -23.75, 25.75 ]
Hall 1993 20 28 (25) 23 14 (9) 80.8 % 14.00 [ 2.44, 25.56 ]
Total (95% CI) 49 55 100.0 % 11.13 [ 0.74, 21.52 ]
Heterogeneity: Chi2 = 1.55, df = 2 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 2.10 (P = 0.036)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours control Favours treatment
(1) Aggarwal 2005 reported geometric means - arithmetic means obtained from authors to allow pooling.
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Analysis 1.10. Comparison 1 Enteral iron supplementation versus no iron supplementation, Outcome 10
Serum ferritin at 6 to 9 months.
Review: Enteral iron supplementation in preterm and low birth weight infants
Comparison: 1 Enteral iron supplementation versus no iron supplementation
Outcome: 10 Serum ferritin at 6 to 9 months
Study or subgroup Treatmtent Control
Mean
Difference
Mean
Difference
N Mean(SD)[mcg/L] N Mean(SD)[mcg/L] IV,Fixed,95% CI IV,Fixed,95% CI
1 2 mg/kg/day
Berglund 2010 (1) 82 49.3 (2.2) 83 18.6 (2.1) 30.70 [ 30.04, 31.36 ]
2 1 mg/kg/day
Berglund 2010 (2) 78 34 (2.1) 83 18.6 (2.1) 15.40 [ 14.75, 16.05 ]
-100 -50 0 50 100
Favours control Favours treatment
(1) Geometric means reported
(2) Geometric means reported
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Analysis 1.11. Comparison 1 Enteral iron supplementation versus no iron supplementation, Outcome 11
MCV at 6 to 9 months.
Review: Enteral iron supplementation in preterm and low birth weight infants
Comparison: 1 Enteral iron supplementation versus no iron supplementation
Outcome: 11 MCV at 6 to 9 months
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD)[fL] N Mean(SD)[fL] IV,Fixed,95% CI IV,Fixed,95% CI
1 2 mg/kg/day iron
Berglund 2010 82 76.8 (3.4) 83 74.3 (4.5) 49.9 % 2.50 [ 1.28, 3.72 ]
Subtotal (95% CI) 82 83 49.9 % 2.50 [ 1.28, 3.72 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.03 (P = 0.000056)
2 1 mg/kg/day iron
Berglund 2010 78 76 (3.3) 83 74.3 (4.5) 50.1 % 1.70 [ 0.49, 2.91 ]
Subtotal (95% CI) 78 83 50.1 % 1.70 [ 0.49, 2.91 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.74 (P = 0.0061)
Total (95% CI) 160 166 100.0 % 2.10 [ 1.24, 2.96 ]
Heterogeneity: Chi2 = 0.83, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 4.79 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.83, df = 1 (P = 0.36), I2 =0.0%
-10 -5 0 5 10
Favours control Favours treatment
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Analysis 1.12. Comparison 1 Enteral iron supplementation versus no iron supplementation, Outcome 12
Transferrin saturation at 6 to 8 weeks.
Review: Enteral iron supplementation in preterm and low birth weight infants
Comparison: 1 Enteral iron supplementation versus no iron supplementation
Outcome: 12 Transferrin saturation at 6 to 8 weeks
Study or subgroup Treatment Control
Mean
Difference
Mean
Difference
N Mean(SD)[%] N Mean(SD)[%] IV,Fixed,95% CI IV,Fixed,95% CI
Hall 1993 20 29 (9) 23 22 (14) 7.00 [ 0.05, 13.95 ]
-100 -50 0 50 100
Favours coontrol Favours treatment
Analysis 1.13. Comparison 1 Enteral iron supplementation versus no iron supplementation, Outcome 13
Transferrin saturation at 3 to 4 months.
Review: Enteral iron supplementation in preterm and low birth weight infants
Comparison: 1 Enteral iron supplementation versus no iron supplementation
Outcome: 13 Transferrin saturation at 3 to 4 months
Study or subgroup Treatment Control
Mean
Difference
Mean
Difference
N Mean(SD)[%] N Mean(SD)[%] IV,Fixed,95% CI IV,Fixed,95% CI
Hall 1993 20 14 (6) 23 18 (11) -4.00 [ -9.21, 1.21 ]
-100 -50 0 50 100
Favours control Favours treatment
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Analysis 1.14. Comparison 1 Enteral iron supplementation versus no iron supplementation, Outcome 14
Transferrin saturation at 6 to 9 months.
Review: Enteral iron supplementation in preterm and low birth weight infants
Comparison: 1 Enteral iron supplementation versus no iron supplementation
Outcome: 14 Transferrin saturation at 6 to 9 months
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD)[%] N Mean(SD)[%] IV,Fixed,95% CI IV,Fixed,95% CI
1 2 mg/kg/day iron
Berglund 2010 82 23.1 (12.6) 83 14 (7.1) 38.6 % 9.10 [ 5.97, 12.23 ]
Subtotal (95% CI) 82 83 38.6 % 9.10 [ 5.97, 12.23 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.71 (P < 0.00001)
2 1 mg/kg/day iron
Berglund 2010 78 19.9 (8.8) 83 14 (7.1) 61.4 % 5.90 [ 3.42, 8.38 ]
Subtotal (95% CI) 78 83 61.4 % 5.90 [ 3.42, 8.38 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.66 (P < 0.00001)
Total (95% CI) 160 166 100.0 % 7.14 [ 5.19, 9.08 ]
Heterogeneity: Chi2 = 2.47, df = 1 (P = 0.12); I2 =60%
Test for overall effect: Z = 7.20 (P < 0.00001)
Test for subgroup differences: Chi2 = 2.47, df = 1 (P = 0.12), I2 =60%
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Analysis 1.15. Comparison 1 Enteral iron supplementation versus no iron supplementation, Outcome 15
Subgroup analyses - Hb at 6 to 8 weeks.
Review: Enteral iron supplementation in preterm and low birth weight infants
Comparison: 1 Enteral iron supplementation versus no iron supplementation
Outcome: 15 Subgroup analyses - Hb at 6 to 8 weeks
Study or subgroup Iron supplementation No iron supplement
Mean
Difference Weight
Mean
Difference
N Mean(SD)[g/L] N Mean(SD)[g/L] IV,Fixed,95% CI IV,Fixed,95% CI
1 Fully formula fed
Gorten 1964 67 106 (8) 66 101 (7) 52.2 % 5.00 [ 2.45, 7.55 ]
Griffin 1999 29 98.5 (15.3) 34 99.6 (15.9) 5.7 % -1.10 [ -8.82, 6.62 ]
Hall 1993 20 97 (15) 23 90 (16) 4.0 % 7.00 [ -2.27, 16.27 ]
Melhorn 1971 70 92.9 (9.6) 67 98.1 (8.6) 36.6 % -5.20 [ -8.25, -2.15 ]
Rudolph 1981 7 72 (7.9) 6 86 (17.1) 1.5 % -14.00 [ -28.88, 0.88 ]
Subtotal (95% CI) 193 196 100.0 % 0.71 [ -1.14, 2.55 ]
Heterogeneity: Chi2 = 31.00, df = 4 (P<0.00001); I2 =87%
Test for overall effect: Z = 0.75 (P = 0.45)
2 Full or partial breast feeding, or not stated
Barclay 1991 16 96 (14.3) 19 96 (17.8) 11.2 % 0.0 [ -10.64, 10.64 ]
Ferlin 1998 20 82.5 (9.9) 20 85.2 (9.7) 34.3 % -2.70 [ -8.77, 3.37 ]
Quilligan 1954 13 120 (6.7) 5 110 (4.4) 45.0 % 10.00 [ 4.70, 15.30 ]
Sankar 2009 21 108 (18) 23 102 (21) 9.5 % 6.00 [ -5.53, 17.53 ]
Subtotal (95% CI) 70 67 100.0 % 4.14 [ 0.59, 7.70 ]
Heterogeneity: Chi2 = 10.24, df = 3 (P = 0.02); I2 =71%
Test for overall effect: Z = 2.28 (P = 0.022)
3 Early commencement
Barclay 1991 16 96 (14.3) 19 96 (17.8) 2.5 % 0.0 [ -10.64, 10.64 ]
Ferlin 1998 20 82.5 (9.9) 20 85.2 (9.7) 7.6 % -2.70 [ -8.77, 3.37 ]
Gorten 1964 67 106 (8) 66 101 (7) 43.1 % 5.00 [ 2.45, 7.55 ]
Hall 1993 20 97 (15) 23 90 (16) 3.3 % 7.00 [ -2.27, 16.27 ]
Melhorn 1971 70 92.9 (9.6) 67 98.1 (8.6) 30.2 % -5.20 [ -8.25, -2.15 ]
Quilligan 1954 13 120 (6.7) 5 110 (4.4) 10.0 % 10.00 [ 4.70, 15.30 ]
Rudolph 1981 7 72 (7.9) 6 86 (17.1) 1.3 % -14.00 [ -28.88, 0.88 ]
Sankar 2009 21 108 (18) 23 102 (21) 2.1 % 6.00 [ -5.53, 17.53 ]
Subtotal (95% CI) 234 229 100.0 % 1.55 [ -0.12, 3.23 ]
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Study or subgroup Iron supplementation No iron supplement
Mean
Difference Weight
Mean
Difference
N Mean(SD)[g/L] N Mean(SD)[g/L] IV,Fixed,95% CI IV,Fixed,95% CI
Heterogeneity: Chi2 = 43.64, df = 7 (P<0.00001); I2 =84%
Test for overall effect: Z = 1.82 (P = 0.069)
4 Late commencement
Griffin 1999 29 98.5 (15.3) 34 99.6 (15.9) 100.0 % -1.10 [ -8.82, 6.62 ]
Subtotal (95% CI) 29 34 100.0 % -1.10 [ -8.82, 6.62 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.28 (P = 0.78)
5 Low dose
Gorten 1964 67 106 (8) 66 101 (7) 87.8 % 5.00 [ 2.45, 7.55 ]
Griffin 1999 29 98.5 (15.3) 34 99.6 (15.9) 9.6 % -1.10 [ -8.82, 6.62 ]
Rudolph 1981 7 72 (7.9) 6 86 (17.1) 2.6 % -14.00 [ -28.88, 0.88 ]
Subtotal (95% CI) 103 106 100.0 % 3.92 [ 1.53, 6.32 ]
Heterogeneity: Chi2 = 7.88, df = 2 (P = 0.02); I2 =75%
Test for overall effect: Z = 3.21 (P = 0.0013)
6 High dose
Barclay 1991 16 96 (14.3) 19 96 (17.8) 4.5 % 0.0 [ -10.64, 10.64 ]
Ferlin 1998 20 82.5 (9.9) 20 85.2 (9.7) 13.7 % -2.70 [ -8.77, 3.37 ]
Hall 1993 20 97 (15) 23 90 (16) 5.9 % 7.00 [ -2.27, 16.27 ]
Melhorn 1971 70 92.9 (9.6) 67 98.1 (8.6) 54.3 % -5.20 [ -8.25, -2.15 ]
Quilligan 1954 13 120 (6.7) 5 110 (4.4) 17.9 % 10.00 [ 4.70, 15.30 ]
Sankar 2009 21 108 (18) 23 102 (21) 3.8 % 6.00 [ -5.53, 17.53 ]
Subtotal (95% CI) 160 157 100.0 % -0.76 [ -3.01, 1.49 ]
Heterogeneity: Chi2 = 28.37, df = 5 (P = 0.00003); I2 =82%
Test for overall effect: Z = 0.66 (P = 0.51)
7 Under 1500 g mean birth weight
Ferlin 1998 20 82.5 (9.9) 20 85.2 (9.7) 40.1 % -2.70 [ -8.77, 3.37 ]
Griffin 1999 29 98.5 (15.3) 34 99.6 (15.9) 24.8 % -1.10 [ -8.82, 6.62 ]
Hall 1993 20 97 (15) 23 90 (16) 17.2 % 7.00 [ -2.27, 16.27 ]
Rudolph 1981 7 72 (7.9) 6 86 (17.1) 6.7 % -14.00 [ -28.88, 0.88 ]
Sankar 2009 21 108 (18) 23 102 (21) 11.1 % 6.00 [ -5.53, 17.53 ]
Subtotal (95% CI) 97 106 100.0 % -0.42 [ -4.27, 3.43 ]
Heterogeneity: Chi2 = 7.42, df = 4 (P = 0.12); I2 =46%
Test for overall effect: Z = 0.21 (P = 0.83)
8 1500 g or over mean birth weight
Barclay 1991 16 96 (14.3) 19 96 (17.8) 3.3 % 0.0 [ -10.64, 10.64 ]
Gorten 1964 67 106 (8) 66 101 (7) 56.9 % 5.00 [ 2.45, 7.55 ]
Melhorn 1971 70 92.9 (9.6) 67 98.1 (8.6) 39.9 % -5.20 [ -8.25, -2.15 ]
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Study or subgroup Iron supplementation No iron supplement
Mean
Difference Weight
Mean
Difference
N Mean(SD)[g/L] N Mean(SD)[g/L] IV,Fixed,95% CI IV,Fixed,95% CI
Subtotal (95% CI) 153 152 100.0 % 0.77 [ -1.16, 2.69 ]
Heterogeneity: Chi2 = 25.28, df = 2 (P<0.00001); I2 =92%
Test for overall effect: Z = 0.78 (P = 0.43)
Test for subgroup differences: Chi2 = 12.18, df = 7 (P = 0.09), I2 =43%
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Analysis 1.16. Comparison 1 Enteral iron supplementation versus no iron supplementation, Outcome 16
Enteral feed intolerance.
Review: Enteral iron supplementation in preterm and low birth weight infants
Comparison: 1 Enteral iron supplementation versus no iron supplementation
Outcome: 16 Enteral feed intolerance
Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Aggarwal 2005 2/32 0/30 4.70 [ 0.23, 94.01 ]
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Analysis 1.17. Comparison 1 Enteral iron supplementation versus no iron supplementation, Outcome 17
Subgroup analyses - Hb at 3 to 4 months.
Review: Enteral iron supplementation in preterm and low birth weight infants
Comparison: 1 Enteral iron supplementation versus no iron supplementation
Outcome: 17 Subgroup analyses - Hb at 3 to 4 months
Study or subgroup Iron supplementation No iron supplement
Mean
Difference Weight
Mean
Difference
N Mean(SD)[g/L] N Mean(SD)[g/L] IV,Fixed,95% CI IV,Fixed,95% CI
1 Fully formula fed
Gorten 1964 55 100 (10) 47 96 (11) 46.9 % 4.00 [ -0.11, 8.11 ]
Griffin 1999 29 105 (9.6) 34 101 (10.2) 33.0 % 4.00 [ -0.90, 8.90 ]
Hall 1993 20 104 (10) 23 108 (11) 20.1 % -4.00 [ -10.28, 2.28 ]
Subtotal (95% CI) 104 104 100.0 % 2.39 [ -0.42, 5.21 ]
Heterogeneity: Chi2 = 4.99, df = 2 (P = 0.08); I2 =60%
Test for overall effect: Z = 1.67 (P = 0.095)
2 Full or partial breast feeding
Aggarwal 2005 13 117 (9) 13 107 (12) 43.8 % 10.00 [ 1.85, 18.15 ]
Barclay 1991 16 101 (12.2) 19 104 (8.9) 56.2 % -3.00 [ -10.19, 4.19 ]
Subtotal (95% CI) 29 32 100.0 % 2.69 [ -2.70, 8.08 ]
Heterogeneity: Chi2 = 5.49, df = 1 (P = 0.02); I2 =82%
Test for overall effect: Z = 0.98 (P = 0.33)
3 Early commencement
Barclay 1991 16 101 (12.2) 19 104 (8.9) 18.6 % -3.00 [ -10.19, 4.19 ]
Gorten 1964 55 100 (10) 47 96 (11) 57.0 % 4.00 [ -0.11, 8.11 ]
Hall 1993 20 104 (10) 23 108 (11) 24.4 % -4.00 [ -10.28, 2.28 ]
Subtotal (95% CI) 91 89 100.0 % 0.75 [ -2.36, 3.85 ]
Heterogeneity: Chi2 = 5.65, df = 2 (P = 0.06); I2 =65%
Test for overall effect: Z = 0.47 (P = 0.64)
4 Late commencement
Aggarwal 2005 13 117 (9) 13 107 (12) 26.5 % 10.00 [ 1.85, 18.15 ]
Griffin 1999 29 105 (9.6) 34 101 (10.2) 73.5 % 4.00 [ -0.90, 8.90 ]
Subtotal (95% CI) 42 47 100.0 % 5.59 [ 1.39, 9.79 ]
Heterogeneity: Chi2 = 1.53, df = 1 (P = 0.22); I2 =35%
Test for overall effect: Z = 2.61 (P = 0.0090)
5 Low dose
Gorten 1964 55 100 (10) 47 96 (11) 58.7 % 4.00 [ -0.11, 8.11 ]
Griffin 1999 29 105 (9.6) 34 101 (10.2) 41.3 % 4.00 [ -0.90, 8.90 ]
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Study or subgroup Iron supplementation No iron supplement
Mean
Difference Weight
Mean
Difference
N Mean(SD)[g/L] N Mean(SD)[g/L] IV,Fixed,95% CI IV,Fixed,95% CI
Subtotal (95% CI) 84 81 100.0 % 4.00 [ 0.85, 7.15 ]
Heterogeneity: Chi2 = 0.0, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 2.49 (P = 0.013)
6 High dose
Aggarwal 2005 13 117 (9) 13 107 (12) 25.2 % 10.00 [ 1.85, 18.15 ]
Barclay 1991 16 101 (12.2) 19 104 (8.9) 32.3 % -3.00 [ -10.19, 4.19 ]
Hall 1993 20 104 (10) 23 108 (11) 42.5 % -4.00 [ -10.28, 2.28 ]
Subtotal (95% CI) 49 55 100.0 % -0.15 [ -4.24, 3.94 ]
Heterogeneity: Chi2 = 8.00, df = 2 (P = 0.02); I2 =75%
Test for overall effect: Z = 0.07 (P = 0.94)
7 Under 1500 g mean birth weight
Griffin 1999 29 105 (9.6) 34 101 (10.2) 62.2 % 4.00 [ -0.90, 8.90 ]
Hall 1993 20 104 (10) 23 108 (11) 37.8 % -4.00 [ -10.28, 2.28 ]
Subtotal (95% CI) 49 57 100.0 % 0.98 [ -2.89, 4.84 ]
Heterogeneity: Chi2 = 3.88, df = 1 (P = 0.05); I2 =74%
Test for overall effect: Z = 0.50 (P = 0.62)
8 1500 g or over birth weight
Aggarwal 2005 13 117 (9) 13 107 (12) 16.1 % 10.00 [ 1.85, 18.15 ]
Barclay 1991 16 101 (12.2) 19 104 (8.9) 20.6 % -3.00 [ -10.19, 4.19 ]
Gorten 1964 55 100 (10) 47 96 (11) 63.3 % 4.00 [ -0.11, 8.11 ]
Subtotal (95% CI) 84 79 100.0 % 3.52 [ 0.25, 6.79 ]
Heterogeneity: Chi2 = 5.63, df = 2 (P = 0.06); I2 =65%
Test for overall effect: Z = 2.11 (P = 0.035)
Test for subgroup differences: Chi2 = 6.77, df = 7 (P = 0.45), I2 =0.0%
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Analysis 2.1. Comparison 2 Early versus late iron supplementation, Outcome 1 Neurodevelopmental
outcome (MPC) at 5 years.
Review: Enteral iron supplementation in preterm and low birth weight infants
Comparison: 2 Early versus late iron supplementation
Outcome: 1 Neurodevelopmental outcome (MPC) at 5 years
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Steinmacher 2007 90 92 (17) 74 89 (16) 100.0 % 3.00 [ -2.06, 8.06 ]
Total (95% CI) 90 74 100.0 % 3.00 [ -2.06, 8.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.16 (P = 0.25)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 Early versus late iron supplementation, Outcome 2 Haemoglobin
concentration at 6 to 8 weeks.
Review: Enteral iron supplementation in preterm and low birth weight infants
Comparison: 2 Early versus late iron supplementation
Outcome: 2 Haemoglobin concentration at 6 to 8 weeks
Study or subgroup Early commencement
Late com-
mence-
ment
Mean
Difference Weight
Mean
Difference
N Mean(SD)[g/L] N Mean(SD)[g/L] IV,Fixed,95% CI IV,Fixed,95% CI
Arnon 2009 62 98 (10) 54 81 (6) 86.3 % 17.00 [ 14.04, 19.96 ]
Jansson 1979 15 103 (10) 13 97 (10) 13.7 % 6.00 [ -1.43, 13.43 ]
Total (95% CI) 77 67 100.0 % 15.49 [ 12.74, 18.24 ]
Heterogeneity: Chi2 = 7.27, df = 1 (P = 0.01); I2 =86%
Test for overall effect: Z = 11.05 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 2.3. Comparison 2 Early versus late iron supplementation, Outcome 3 Haemoglobin
concentration at 6 to 9 months.
Review: Enteral iron supplementation in preterm and low birth weight infants
Comparison: 2 Early versus late iron supplementation
Outcome: 3 Haemoglobin concentration at 6 to 9 months
Study or subgroup Early commencement
Late com-
mence-
ment
Mean
Difference
Mean
Difference
N Mean(SD)[g/L] N Mean(SD)[g/L] IV,Fixed,95% CI IV,Fixed,95% CI
Jansson 1979 10 115 (7) 9 115 (5) 0.0 [ -5.43, 5.43 ]
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Analysis 2.4. Comparison 2 Early versus late iron supplementation, Outcome 4 Ferritin level at 6 to 8 weeks.
Review: Enteral iron supplementation in preterm and low birth weight infants
Comparison: 2 Early versus late iron supplementation
Outcome: 4 Ferritin level at 6 to 8 weeks
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mcg/L] N Mean(SD)[mcg/L] IV,Fixed,95% CI IV,Fixed,95% CI
Arnon 2009 62 58 (26) 54 33 (18) 100.0 % 25.00 [ 16.94, 33.06 ]
Total (95% CI) 62 54 100.0 % 25.00 [ 16.94, 33.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 6.08 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 3.1. Comparison 3 High dose versus low dose iron supplementation, Outcome 1
Neurodevelopmental outcome (Grifiths Developmental Assessment score) at 12 months or less.
Review: Enteral iron supplementation in preterm and low birth weight infants
Comparison: 3 High dose versus low dose iron supplementation
Outcome: 1 Neurodevelopmental outcome (Grifiths Developmental Assessment score) at 12 months or less
Study or subgroup High dose Low dose
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Friel 2001 20 118 (11) 22 118 (10) 0.0 [ -6.38, 6.38 ]
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Analysis 3.2. Comparison 3 High dose versus low dose iron supplementation, Outcome 2 Haemoglobin
concentration at 6 to 8 weeks.
Review: Enteral iron supplementation in preterm and low birth weight infants
Comparison: 3 High dose versus low dose iron supplementation
Outcome: 2 Haemoglobin concentration at 6 to 8 weeks
Study or subgroup High dose Low dose
Mean
Difference Weight
Mean
Difference
N Mean(SD)[g/L] N Mean(SD)[g/L] IV,Fixed,95% CI IV,Fixed,95% CI
1 Full formula feeding
Friel 2001 20 108 (20) 21 113 (22) 28.2 % -5.00 [ -17.86, 7.86 ]
Subtotal (95% CI) 20 21 28.2 % -5.00 [ -17.86, 7.86 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.76 (P = 0.45)
2 Full or partial breast feeding, or not stated
Barclay 1991 20 96 (9.1) 16 96 (14.3) 71.8 % 0.0 [ -8.06, 8.06 ]
Subtotal (95% CI) 20 16 71.8 % 0.0 [ -8.06, 8.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Total (95% CI) 40 37 100.0 % -1.41 [ -8.24, 5.42 ]
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Study or subgroup High dose Low dose
Mean
Difference Weight
Mean
Difference
N Mean(SD)[g/L] N Mean(SD)[g/L] IV,Fixed,95% CI IV,Fixed,95% CI
Heterogeneity: Chi2 = 0.42, df = 1 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 0.40 (P = 0.69)
Test for subgroup differences: Chi2 = 0.42, df = 1 (P = 0.52), I2 =0.0%
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Analysis 3.3. Comparison 3 High dose versus low dose iron supplementation, Outcome 3 Haemoglobin
concentration at 3 to 4 months.
Review: Enteral iron supplementation in preterm and low birth weight infants
Comparison: 3 High dose versus low dose iron supplementation
Outcome: 3 Haemoglobin concentration at 3 to 4 months
Study or subgroup High dose Low dose
Mean
Difference Weight
Mean
Difference
N Mean(SD)[g/L] N Mean(SD)[g/L] IV,Fixed,95% CI IV,Fixed,95% CI
1 Full formula feeding
Friel 2001 20 123 (9) 25 118 (8) 52.4 % 5.00 [ -0.04, 10.04 ]
Groh-Wargo 1990 18 118 (11) 18 115 (11) 25.7 % 3.00 [ -4.19, 10.19 ]
Subtotal (95% CI) 38 43 78.1 % 4.34 [ 0.21, 8.47 ]
Heterogeneity: Chi2 = 0.20, df = 1 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 2.06 (P = 0.039)
2 Full or partial breast feeding, or not stated
Barclay 1991 20 106 (11.4) 16 101 (12.2) 21.9 % 5.00 [ -2.79, 12.79 ]
Subtotal (95% CI) 20 16 21.9 % 5.00 [ -2.79, 12.79 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.26 (P = 0.21)
Total (95% CI) 58 59 100.0 % 4.49 [ 0.84, 8.13 ]
Heterogeneity: Chi2 = 0.22, df = 2 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 2.41 (P = 0.016)
Test for subgroup differences: Chi2 = 0.02, df = 1 (P = 0.88), I2 =0.0%
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Analysis 3.4. Comparison 3 High dose versus low dose iron supplementation, Outcome 4 Haemoglobin
concentration at 6 to 9 months.
Review: Enteral iron supplementation in preterm and low birth weight infants
Comparison: 3 High dose versus low dose iron supplementation
Outcome: 4 Haemoglobin concentration at 6 to 9 months
Study or subgroup High dose Low dose
Mean
Difference
Mean
Difference
N Mean(SD)[g/L] N Mean(SD)[g/L] IV,Fixed,95% CI IV,Fixed,95% CI
Friel 2001 20 126 (9) 20 122 (9) 4.00 [ -1.58, 9.58 ]
-4 -2 0 2 4
Favours low dose Favours high dose
Analysis 3.5. Comparison 3 High dose versus low dose iron supplementation, Outcome 5 Haemoglobin
concentration at 12 months.
Review: Enteral iron supplementation in preterm and low birth weight infants
Comparison: 3 High dose versus low dose iron supplementation
Outcome: 5 Haemoglobin concentration at 12 months
Study or subgroup High dose Low dose
Mean
Difference
Mean
Difference
N Mean(SD)[g/L] N Mean(SD)[g/L] IV,Fixed,95% CI IV,Fixed,95% CI
Friel 2001 20 125 (9) 22 127 (8) -2.00 [ -7.17, 3.17 ]
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Analysis 3.6. Comparison 3 High dose versus low dose iron supplementation, Outcome 6 Mean corpuscular
volume at 3 to 4 months.
Review: Enteral iron supplementation in preterm and low birth weight infants
Comparison: 3 High dose versus low dose iron supplementation
Outcome: 6 Mean corpuscular volume at 3 to 4 months
Study or subgroup High dose Low dose
Mean
Difference
Mean
Difference
N Mean(SD)[fL] N Mean(SD)[fL] IV,Fixed,95% CI IV,Fixed,95% CI
Groh-Wargo 1990 18 87.6 (4.7) 18 84.3 (5.2) 3.30 [ 0.06, 6.54 ]
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Analysis 3.7. Comparison 3 High dose versus low dose iron supplementation, Outcome 7 Serum ferritin at
6 to 8 weeks.
Review: Enteral iron supplementation in preterm and low birth weight infants
Comparison: 3 High dose versus low dose iron supplementation
Outcome: 7 Serum ferritin at 6 to 8 weeks
Study or subgroup High dose Low dose
Mean
Difference
Mean
Difference
N Mean(SD)[mcg/L] N Mean(SD)[mcg/L] IV,Fixed,95% CI IV,Fixed,95% CI
Friel 2001 21 57 (45) 21 62 (48) -5.00 [ -33.14, 23.14 ]
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Analysis 3.8. Comparison 3 High dose versus low dose iron supplementation, Outcome 8 Serum ferritin at
3 to 4 months.
Review: Enteral iron supplementation in preterm and low birth weight infants
Comparison: 3 High dose versus low dose iron supplementation
Outcome: 8 Serum ferritin at 3 to 4 months
Study or subgroup High dose Low dose
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mcg/L] N Mean(SD)[mcg/L] IV,Fixed,95% CI IV,Fixed,95% CI
Friel 2001 21 21 (18) 25 16 (8) 89.5 % 5.00 [ -3.31, 13.31 ]
Groh-Wargo 1990 18 42.2 (34.1) 18 45.3 (40.1) 10.5 % -3.10 [ -27.42, 21.22 ]
Total (95% CI) 39 43 100.0 % 4.15 [ -3.71, 12.02 ]
Heterogeneity: Chi2 = 0.38, df = 1 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 1.03 (P = 0.30)
Test for subgroup differences: Not applicable
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Analysis 3.9. Comparison 3 High dose versus low dose iron supplementation, Outcome 9 Serum ferritin at
6 to 9 months.
Review: Enteral iron supplementation in preterm and low birth weight infants
Comparison: 3 High dose versus low dose iron supplementation
Outcome: 9 Serum ferritin at 6 to 9 months
Study or subgroup High dose Low dose
Mean
Difference
Mean
Difference
N Mean(SD)[mcg/L] N Mean(SD)[mcg/L] IV,Fixed,95% CI IV,Fixed,95% CI
Friel 2001 20 15 (8) 22 11 (4) 4.00 [ 0.12, 7.88 ]
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Analysis 3.10. Comparison 3 High dose versus low dose iron supplementation, Outcome 10 Serum ferritin
at 12 months.
Review: Enteral iron supplementation in preterm and low birth weight infants
Comparison: 3 High dose versus low dose iron supplementation
Outcome: 10 Serum ferritin at 12 months
Study or subgroup High dose Low dose
Mean
Difference
Mean
Difference
N Mean(SD)[mcg/L] N Mean(SD)[mcg/L] IV,Fixed,95% CI IV,Fixed,95% CI
Friel 2001 20 17 (11) 21 19 (7) -2.00 [ -7.67, 3.67 ]
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Analysis 3.11. Comparison 3 High dose versus low dose iron supplementation, Outcome 11 Transferrin
saturation at 6 to 8 weeks.
Review: Enteral iron supplementation in preterm and low birth weight infants
Comparison: 3 High dose versus low dose iron supplementation
Outcome: 11 Transferrin saturation at 6 to 8 weeks
Study or subgroup High dose Low dose
Mean
Difference
Mean
Difference
N Mean(SD)[%] N Mean(SD)[%] IV,Fixed,95% CI IV,Fixed,95% CI
Friel 2001 27 22 (12) 25 32 (16) -10.00 [ -17.73, -2.27 ]
-10 -5 0 5 10
Favours low dose Favours high dose
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Analysis 3.12. Comparison 3 High dose versus low dose iron supplementation, Outcome 12 Transferrin
saturation at 3 to 4 months.
Review: Enteral iron supplementation in preterm and low birth weight infants
Comparison: 3 High dose versus low dose iron supplementation
Outcome: 12 Transferrin saturation at 3 to 4 months
Study or subgroup High dose Low dose
Mean
Difference Weight
Mean
Difference
N Mean(SD)[%] N Mean(SD)[%] IV,Fixed,95% CI IV,Fixed,95% CI
Friel 2001 24 18 (5) 25 16 (7) 76.5 % 2.00 [ -1.40, 5.40 ]
Groh-Wargo 1990 18 24.3 (10.2) 18 23.4 (8.5) 23.5 % 0.90 [ -5.23, 7.03 ]
Total (95% CI) 42 43 100.0 % 1.74 [ -1.23, 4.71 ]
Heterogeneity: Chi2 = 0.09, df = 1 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 1.15 (P = 0.25)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours low dose Favours high dose
Analysis 3.13. Comparison 3 High dose versus low dose iron supplementation, Outcome 13 Transferrin
saturation at 6 to 9 months.
Review: Enteral iron supplementation in preterm and low birth weight infants
Comparison: 3 High dose versus low dose iron supplementation
Outcome: 13 Transferrin saturation at 6 to 9 months
Study or subgroup High dose Low dose
Mean
Difference
Mean
Difference
N Mean(SD)[%] N Mean(SD)[%] IV,Fixed,95% CI IV,Fixed,95% CI
Friel 2001 20 20 (9) 21 18 (7) 2.00 [ -2.95, 6.95 ]
-10 -5 0 5 10
Favours low dose Favours high dose
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Analysis 3.14. Comparison 3 High dose versus low dose iron supplementation, Outcome 14 Transferrin
saturation at 12 months.
Review: Enteral iron supplementation in preterm and low birth weight infants
Comparison: 3 High dose versus low dose iron supplementation
Outcome: 14 Transferrin saturation at 12 months
Study or subgroup High dose Low dose
Mean
Difference
Mean
Difference
N Mean(SD)[%] N Mean(SD)[%] IV,Fixed,95% CI IV,Fixed,95% CI
Friel 2001 20 20 (8) 20 22 (8) -2.00 [ -6.96, 2.96 ]
-10 -5 0 5 10
Favours low dose Favours high dose
Analysis 4.1. Comparison 4 Short duration versus long duration iron supplementation, Outcome 1
Haemoglobin at 6 to 8 weeks.
Review: Enteral iron supplementation in preterm and low birth weight infants
Comparison: 4 Short duration versus long duration iron supplementation
Outcome: 1 Haemoglobin at 6 to 8 weeks
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD)[g/L] N Mean(SD)[g/L] IV,Fixed,95% CI IV,Fixed,95% CI
Griffin 1999 29 98.5 (15.3) 15 94.8 (9.9) 100.0 % 3.70 [ -3.79, 11.19 ]
Total (95% CI) 29 15 100.0 % 3.70 [ -3.79, 11.19 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.97 (P = 0.33)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours control Favours treatment
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Analysis 4.2. Comparison 4 Short duration versus long duration iron supplementation, Outcome 2
Haemoglobin at 3 to 4 months.
Review: Enteral iron supplementation in preterm and low birth weight infants
Comparison: 4 Short duration versus long duration iron supplementation
Outcome: 2 Haemoglobin at 3 to 4 months
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD)[g/L] N Mean(SD)[g/L] IV,Fixed,95% CI IV,Fixed,95% CI
Griffin 1999 29 105.1 (9.6) 15 103.6 (8.2) 100.0 % 1.50 [ -3.92, 6.92 ]
Total (95% CI) 29 15 100.0 % 1.50 [ -3.92, 6.92 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.54 (P = 0.59)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours control Favours treatment
Analysis 4.3. Comparison 4 Short duration versus long duration iron supplementation, Outcome 3
Haemoglobin at 6 to 9 months.
Review: Enteral iron supplementation in preterm and low birth weight infants
Comparison: 4 Short duration versus long duration iron supplementation
Outcome: 3 Haemoglobin at 6 to 9 months
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD)[g/L] N Mean(SD)[g/L] IV,Fixed,95% CI IV,Fixed,95% CI
Griffin 1999 29 120.5 (8.6) 15 114.8 (8.2) 100.0 % 5.70 [ 0.50, 10.90 ]
Total (95% CI) 29 15 100.0 % 5.70 [ 0.50, 10.90 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.15 (P = 0.032)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours control Favours treatment
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A D D I T I O N A L T A B L E S
Table 1. Summary of results by study
Study Primary outcome Secondary outcomes
Aggarwal 2005 • Haemoglobin concentration: favoured iron
supplementation group at 4 months postnatal, but
not 3 months postnatal. Greater increase in
haemoglobin from baseline at 3 months postnatal
(not significant at 4 months postnatal)
• Peripheral smear, serum ferritin, weight, length,
head circumference: no differences
Arnon 2009 • Alpha-tocopherol levels: no difference at 2, 4
and 8 weeks
• Iron, ferritin and reticulocyte count: higher in
early iron group at 8 weeks; no difference at 2 and 4
weeks
• Haemoglobin level: higher in early iron group at
4 and 8 weeks
• Serum transferrin receptor level: lower in early
iron group at 4 and 8 weeks
• Proportion of subjects having transfusions
during study period: fewer in early iron group at 4
and 8 weeks
Barclay 1991 • Erythrocyte superoxide dismutase levels: lower
activity in high iron group when compared with iron
supplementation and no iron supplementation
groups, but not in iron supplementation versus no
iron supplementation groups
• Haemoglobin concentration and reticulocyte
count: no difference
• Plasma copper and zinc levels: no difference
• Plasma ferritin levels: increased in high iron
group compared with no iron supplementation
group, but not significantly increased in iron
supplementation group
• Weight, length and head circumference: no
difference
Berglund 2010 • Haemoglobin level (at 6 months): high iron
group > low iron group > no iron group
• MCV: high iron group > no iron group; low
iron group > no iron group
• Ferritin: high iron group > low iron group > no
iron group
• Iron level: high iron group > no iron group; low
iron group > no iron group
• Transferrin saturation: high iron group > no iron
group; low iron group > no iron group
• Transferrin level and transferrin receptor level:
low iron group < no iron; high iron group < no iron
group
• Growth (weight, length, head circumference,
knee-heel length): no differences
Berseth 2004 • Weight gain: no difference • Length and head circumference: no difference
• Haematocrit, albumin, transthyretin, alkaline
phosphatase, BUN, triglycerides, sodium, potassium,
chloride, bicarbonate, calcium, phosphorus,
magnesium, zinc, copper, ferritin and vitamin D: no
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Table 1. Summary of results by study (Continued)
difference
• Incidence of feed intolerance (gastric residuals,
abdominal distention and emesis): no difference
• Incidence of NEC: no difference
• Need for blood transfusion: lower in iron
supplementation group from days 15-28
Coles 1954 • Haemoglobin concentration: higher at 4, 5 and
6 months in iron supplementation group. Fewer
infants in the iron supplementation and red blood cell
count
Diamond 1958 • Haemoglobin concentration: no difference
Ferlin 1998 • Haemoglobin concentration and hematocrit: no
difference
• Weight, length and head circumference: no
difference
• Reticulocytes, platelets and red cell resistance to
hydrogen peroxide: no difference
Franz 2000 • Serum ferritin: no difference
• Incidence of iron deficiency: increased in no iron
supplementation group
• Transferrin, transferrin saturation, hematocrit:
no difference
• Reticulocytes: higher in iron supplementation
group
• Number of transfusions required and blood
volume transfused (after day 14): lower in iron
supplementation group
Friel 2001 • Griffith Developmental Assessment score: no
difference
• Weight, height: no difference.
• Haemoglobin level, hematocrit, ferritin,
transferrin, transferrin saturation and plasma iron: no
difference
• Malondialdehyde level, catalase level: no
difference
• Plasma zinc and copper levels: lower in high iron
group, but not statistically significant
• Red blood cell fragility, superoxide dismutase
level: no difference
• Glutathione peroxidase level: slightly higher in
high iron group
Gorten 1964 • Incidence of iron deficiency: lower in the iron
supplementation group
• Haemoglobin concentration, red blood cell
count, hematocrit, MCV, MCH, MCHC: higher in
the iron supplementation group from 10 to 14 weeks
Griffin 1999 • Haemoglobin concentration: no difference
• Plasma ferritin: no difference
Groh-Wargo 1990 • Weight: no difference
• Haemoglobin, MCV, FEP, transferrin saturation
and ferritin: no difference
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Table 1. Summary of results by study (Continued)
Gross 1985 • Serum vitamin E concentration: lower in the
iron supplementation group. Also lower in infant
formula group compared with breast milk, and
mature milk compared with preterm milk
• Vitamin E/lipid ratio, hydrogen peroxide
haemolysis, Haematocrit, reticulocyte count: no
difference between iron supplementation and no iron
supplementation group
Hall 1993 • Plasma ferritin: higher in high iron group
• Transferrin saturation: no difference
• Serum iron: no difference
• Transferrin: no difference between high iron and
low iron groups
• Haemoglobin, hematocrit, red blood cell count,
MCH and reticulocyte count: no difference
• MCV and MCHC: higher in high iron group
• Weight, length, head circumference, arm
circumference and triceps skinfold thickness: no
difference
Halliday 1983 • Iron intake, haemoglobin concentration, serum
iron, serum transferrin and serum ferritin: no
difference between iron supplementation and no iron
supplementation group, nor between early iron and
late iron group
Hanninen 1961 • Haemoglobin, MCH: both higher in the iron
supplementation group from 3 to 6 months postnatal
Jansson 1979 • Serum ferritin: no difference • Haemoglobin concentration, reticulocyte count,
platelet count: no difference
Lundstrom 1977 • Haemoglobin concentration, MCV, transferrin
saturation: higher in iron supplementation group
from 3 months postnatal
• Serum ferritin: higher in iron supplementation
group from 2 months postnatal
• Reticulocyte count, platelet count: no difference
Melhorn 1971 • Haemoglobin: decreased in iron
supplementation group (without vitamin E), but this
effect ameliorated by addition of vitamin E
• Reticulocyte count: increased in iron
supplementation group (without vitamin E), but
effect ameliorated from 8 weeks by addition of
vitamin E
• Platelet count: higher in non-vitamin E
supplemented group
• Red cell fragility: higher in non-vitamin E
supplemented group, but not in iron supplemented
group
• Serum tocopherol: no difference between iron
groups, but higher in vitamin E supplemented groups
Melnick 1988 • Haemoglobin concentration: no difference
• Serum ferritin: higher in iron supplementation
82Enteral iron supplementation in preterm and low birth weight infants (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 1. Summary of results by study (Continued)
group at 29 days
• Transferrin concentration: no difference
Quilligan 1954 • Haemoglobin concentration, hematocrit: higher
in iron supplementation group
• Red blood cell count, reticulocyte count: no
difference
• Weight: higher in no iron supplementation
group at 11 to 20 days, but not thereafter
Reedy 1952 • Red cell count: no difference, except at 5
months when RBC count was higher in iron
supplementation group
• Haemoglobin concentration: higher in iron
supplementation group
• Leukocyte count, eosinophil count: no
difference (note: low rate of follow-up)
• Weight: lower in the no iron supplementation
group (low rate of follow-up)
Rudolph 1981 • Haemoglobin, hematocrit, reticulocytes,
hydrogen peroxide haemolysis, serum cholesterol and
serum vitamin E: no difference
• Red cell and plasma selenium: from weeks 4 to 6
postnatally, red cell selenium was higher in the iron
supplementation group. Otherwise, no difference
Sankar 2009 • Serum ferritin at 60 days of age: no difference • Haemoglobin and hematocrit: no difference
• Neonatal morbidities: no difference
• Weight: no difference
• Blood transfusion, re-hospitalisation and sepsis/
pneumonia: no difference
Steinmacher 2007 • As per Franz 2000 • As per Franz 2000, plus additional measures at 5
years of age
• neurologic examination: higher proportion
normal in early iron group
• Weight, length, head circumference, mobility,
cognitive development, composite outcomes:no
difference
WH A T ’ S N E W
Last assessed as up-to-date: 12 August 2011.
Date Event Description
17 April 2012 Amended Table 1 ’Summary of results by study’ linked to text.
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H I S T O R Y
Protocol first published: Issue 1, 2005
Review first published: Issue 3, 2012
Date Event Description
4 February 2010 Amended Converted to new review format
4 December 2007 New citation required and conclusions have changed Substantive amendment
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